Tim Ibbotson
Research Subjects
Tim Ibbotson has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Caroline M. Perry
Adis International Limited
7 shared publicationsKaren L. Goa
Adis International Limited, Mairangi Bay, New Zealand
5 shared publicationsAntona J. Wagstaff
Adis International Limited
3 shared publicationsJane K. McGavin
Adis International Inc
3 shared publicationsDavid R. Goldsmith
Adis International Limited, Auckland, New Zealand
2 shared publicationsG. Edwards
Department of Physiological Sciences, University of Manchester
2 shared publications
Latest Publications
- 1 January 2004
- Published by Springer Nature in CNS Drugs
- Vol. 18 (1) , 63-67
Spotlight on Lamotrigine in Bipolar Disorder1
Lamotrigine (Lamictal®), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder....
- 1 January 2004
- Published by Springer Nature in CNS Drugs
- Vol. 18 (1) , 63-67
Spotlight on Lamotrigine in Bipolar Disorder1
Lamotrigine (Lamictal®), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder....
- 1 January 2003
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 3 (5) , 381-386
Spotlight on Abciximab in Patients with Ischemic Heart Disease Undergoing Percutaneous Coronary Revascularization1
Abciximab (Reopro®) is an antibody fragment that dose-dependently inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein (GP) IIb/IIIa, vitronectin and Mac-1 receptors. Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) showed greater efficacy than tirofiban in reducing the 30-day composite endpoint of death, nonfatal myocardial infarction (MI) or urgent target-vessel revascularization in the randomized, double-blind TARGET study in patients scheduled for stent placement. In addition, the beneficial effects of treatment with abciximab previously observed in the randomized, multicenter, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischemic complications relative to placebo consistently observed across a range of subgroups including age, sex, bodyweight and indication for revascularization. The incidence of the composite endpoint was reduced in patients presenting with acute MI of ‘48 hours’ duration in comparison with either fibrinolytic therapy or stenting alone in the randomized STOPAMI and ADMIRAL trials, primarily because of a reduced requirement for urgent repeat revascularization and reduced incidence of mortality. In the randomized, nonblind, multicenter CADILLAC trial in patients with acute myocardial infarction (MI), stenting alone was superior to percutaneous transluminal coronary angioplasty (PTCA) and stenting alone was not inferior to PTCA plus abciximab. Recent large randomized, multicenter studies (ASSENT-3 and GUSTO-V) have shown higher efficacy (on various ischemic endpoints) of abciximab in combination with either a reduced dose of tenecteplase or reteplase compared with the fibrinolytic drug alone. TIMI grade 3 flow rates at 60 and 90 minutes in the TIMI-14 and SPEED trials were higher in patients who received abciximab in combination with either alteplase or reteplase than abciximab alone and were similar to that seen with the full-dose fibrinolytic alone. In the randomized, multicenter GUSTO IV-ACS study, no significant differences in any of the ischemic endpoints at either 7 or 30 days in patients with acute coronary syndromes who were not scheduled to undergo early revascularization (within 12 hours of end of infusion) were apparent between those who received abciximab (bolus and either 24- or 48-hour infusion) and those who received placebo in addition to aspirin and heparin. The most common adverse events associated with the use of abciximab are bleeding complications and thrombocytopenia, although the risk of major bleeding can be limited through adhering to current administration protocols. Treatment costs are generally higher in both stent plus abciximab and angioplasty plus abciximab groups than stent plus placebo, primarily because of the acquisition cost of abciximab. Abciximab appeared most cost beneficial in high-risk patients undergoing elective percutaneous coronary revascularization; among lower risk patients, abciximab therapy has been associated with higher total in-hospital and 6-month medical costs than eptifibatide. The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischemic complications in patients with ischemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. High-risk patients (including those with diabetes mellitus) derive particular benefits from abciximab treatment. Abciximab remains an important therapeutic option for the prevention of complications in patients with ischaemic heart disease.
- 1 January 2003
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 3 (5) , 381-386
Spotlight on Abciximab in Patients with Ischemic Heart Disease Undergoing Percutaneous Coronary Revascularization1
Abciximab (Reopro®) is an antibody fragment that dose-dependently inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein (GP) IIb/IIIa, vitronectin and Mac-1 receptors. Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) showed greater efficacy than tirofiban in reducing the 30-day composite endpoint of death, nonfatal myocardial infarction (MI) or urgent target-vessel revascularization in the randomized, double-blind TARGET study in patients scheduled for stent placement. In addition, the beneficial effects of treatment with abciximab previously observed in the randomized, multicenter, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischemic complications relative to placebo consistently observed across a range of subgroups including age, sex, bodyweight and indication for revascularization. The incidence of the composite endpoint was reduced in patients presenting with acute MI of ‘48 hours’ duration in comparison with either fibrinolytic therapy or stenting alone in the randomized STOPAMI and ADMIRAL trials, primarily because of a reduced requirement for urgent repeat revascularization and reduced incidence of mortality. In the randomized, nonblind, multicenter CADILLAC trial in patients with acute myocardial infarction (MI), stenting alone was superior to percutaneous transluminal coronary angioplasty (PTCA) and stenting alone was not inferior to PTCA plus abciximab. Recent large randomized, multicenter studies (ASSENT-3 and GUSTO-V) have shown higher efficacy (on various ischemic endpoints) of abciximab in combination with either a reduced dose of tenecteplase or reteplase compared with the fibrinolytic drug alone. TIMI grade 3 flow rates at 60 and 90 minutes in the TIMI-14 and SPEED trials were higher in patients who received abciximab in combination with either alteplase or reteplase than abciximab alone and were similar to that seen with the full-dose fibrinolytic alone. In the randomized, multicenter GUSTO IV-ACS study, no significant differences in any of the ischemic endpoints at either 7 or 30 days in patients with acute coronary syndromes who were not scheduled to undergo early revascularization (within 12 hours of end of infusion) were apparent between those who received abciximab (bolus and either 24- or 48-hour infusion) and those who received placebo in addition to aspirin and heparin. The most common adverse events associated with the use of abciximab are bleeding complications and thrombocytopenia, although the risk of major bleeding can be limited through adhering to current administration protocols. Treatment costs are generally higher in both stent plus abciximab and angioplasty plus abciximab groups than stent plus placebo, primarily because of the acquisition cost of abciximab. Abciximab appeared most cost beneficial in high-risk patients undergoing elective percutaneous coronary revascularization; among lower risk patients, abciximab therapy has been associated with higher total in-hospital and 6-month medical costs than eptifibatide. The GP IIb/IIIa receptor antagonist abciximab, when used with aspirin and heparin, has demonstrated efficacy in reducing the short- and long-term risk of ischemic complications in patients with ischemic heart disease undergoing percutaneous coronary intervention, when used with aspirin and heparin. High-risk patients (including those with diabetes mellitus) derive particular benefits from abciximab treatment. Abciximab remains an important therapeutic option for the prevention of complications in patients with ischaemic heart disease.
- 1 January 2003
- Published by Springer Nature in Disease Management and Health Outcomes
- Vol. 11 (11) , 745-765
Management of Rheumatoid Arthritis
- 1 January 2003
- Published by Springer Nature in Disease Management and Health Outcomes
- Vol. 11 (11) , 745-765
Management of Rheumatoid Arthritis
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (11) , 1089-1098
Lamivudine/Zidovudine/Abacavir
▴ The triple combination tablet containing lamivudine (150mg), zidovudine (300mg) and abacavir (300mg, as abacavir sulfate) is a new formulation of three nucleoside analogue reverse transcriptase inhibitors. ▴ Two studies in treatment-naive patients (one double-blind, one nonblind) have reported that lamivudine/zidovudine (dual combination tablet) plus abacavir showed efficacy similar to that of lamivudine/zidovudine plus indinavir. In both studies, similar numbers of patients in each treatment group had plasma HIV RNA levels <400 copies/mL at week 48 (51% vs 51% and 64% vs 50%). ▴ In treatment-experienced patients with baseline plasma HIV RNA levels 400 copies/mL, was reported in 22% of patients in both treatment groups at week 48. ▴ Treatment-naive patients receiving lamivudine/zidovudine/abacavir combination therapy experienced several adverse events, including nausea, malaise/fatigue and vomiting.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (11) , 1089-1098
Lamivudine/Zidovudine/Abacavir
▴ The triple combination tablet containing lamivudine (150mg), zidovudine (300mg) and abacavir (300mg, as abacavir sulfate) is a new formulation of three nucleoside analogue reverse transcriptase inhibitors. ▴ Two studies in treatment-naive patients (one double-blind, one nonblind) have reported that lamivudine/zidovudine (dual combination tablet) plus abacavir showed efficacy similar to that of lamivudine/zidovudine plus indinavir. In both studies, similar numbers of patients in each treatment group had plasma HIV RNA levels <400 copies/mL at week 48 (51% vs 51% and 64% vs 50%). ▴ In treatment-experienced patients with baseline plasma HIV RNA levels 400 copies/mL, was reported in 22% of patients in both treatment groups at week 48. ▴ Treatment-naive patients receiving lamivudine/zidovudine/abacavir combination therapy experienced several adverse events, including nausea, malaise/fatigue and vomiting.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (2) , 217-236
Capecitabine
Capecitabine is an orally administered prodrug of fluorouracil which is indicated in the US and Europe, in combination with docetaxel, for the treatment of patients with metastatic breast cancer failing anthracycline therapy, and as monotherapy for metastatic breast cancer resistant to paclitaxel and anthracycline therapy (US) or failing intensive chemotherapy (Europe). Capecitabine is also approved for use in metastatic colorectal cancer. Capecitabine is metabolically activated preferentially at the tumour site, and shows antineoplastic activity and synergy with other cytotoxic agents including cyclophosphamide or docetaxel in animal models. Bioavailability after oral administration is close to 100%. In patients with pretreated advanced breast cancer, capecitabine is effective as monotherapy and also in combination with other agents. Combination therapy with capecitabine 1250 mg/m2 twice daily for 2 weeks of every 3-week cycle plus intravenous docetaxel 75 mg/m2 on day one of each cycle was superior to intravenous monotherapy with docetaxel 100 mg/m2 on day one of each cycle. Capecitabine plus docetaxel significantly reduced the risks of disease progression and death by 35% (p = 0.0001) and 23% (p < 0.05), respectively, and significantly increased median survival (p < 0.05) and objective response rates (p < 0.01). Efficacy has also been demonstrated with capecitabine monotherapy and combination therapy in previously untreated patients in preliminary trials. The most common adverse effects occurring in patients receiving capecitabine monotherapy include lymphopenia, anaemia, diarrhoea, hand-and-foot syndrome, nausea, fatigue, hyperbilirubinaemia, dermatitis and vomiting (all >25% incidence). While gastrointestinal events and hand-and-foot syndrome occurred more often with capecitabine than with paclitaxel or a regimen of cyclophosphamide, methotrexate and fluorouracil (CMF), neutropenic fever, arthralgia, pyrexia and myalgia were more common with paclitaxel, and nausea, stomatitis, alopecia and asthenia were more common with CMF. The incidence of adverse effects and hospitalisation was similar in patients receiving capecitabine plus docetaxel and those receiving docetaxel monotherapy. In conclusion, capecitabine, an oral prodrug of fluorouracil which is activated preferentially at the tumour site, is an effective and convenient addition to the intravenous polychemotherapeutic treatment of advanced breast cancer in pretreated patients, and also has potential as a component of first-line combination regimens. Combined capecitabine plus docetaxel therapy resulted in similar rates of treatment-related adverse effects and hospitalisation to those seen with docetaxel monotherapy. Capecitabine is also effective as monotherapy in pretreated patients and phase II data for capecitabine as first-line monotherapy are also promising. While gastrointestinal effects and hand-and-foot syndrome occur often with capecitabine, the tolerability profile was comparatively favourable for other adverse effects (notably, neutropenia and alopecia). Capecitabine is an oral fluoropyrimidine which undergoes several metabolic changes in vivo, ultimately yielding fluorouracil. This occurs preferentially in tumour tissue and leads to subsequent formation of fluorodeoxyuridine mono-phosphate and fluorouridine triphosphate. Capecitabine demonstrates antineoplastic activity in human mammary tumour xenograft models, with synergistic effects when used in combination with other cytotoxic agents including cyclophosphamide and docetaxel. Pharmacokinetic studies with capecitabine have been performed in patients with solid tumours, many of which were colorectal but including some breast tumours. The oral bioavailability of capecitabine is nearly 100%. Maximum plasma concentrations and area under the plasma concentration-time curve (AUC) of capecitabine showed linear increases with dosage and were decreased when capecitabine was administered with food. Elimination of capecitabine is primarily renal; in patients with severe renal impairment, use of capecitabine is contraindicated. Capecitabine increased the AUC and decreased clearance of a single dose of warfarin. Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy therefore require frequent monitoring of their anticoagulant response. The pharmacokinetics of capecitabine are not significantly affected by paclitaxel or docetaxel. Oral capecitabine 1250 or 1255 mg/m2 twice daily for 2 weeks in every 3 has shown efficacy in prospective trials as monotherapy in patients with pretreated advanced breast cancer. Objective response rates with capecitabine monotherapy were 36% (vs a similar rate of 26% with intravenous paclitaxel 175 mg/m2 every 3 weeks) in women with disease resistant to or failing anthracycline therapy, 18 to 41% in those with disease resistant to or failing taxane therapy, and 43, 57 and 70% in those with relapsed disease after high-dose chemotherapy plus autologous stem cell support. A randomised nonblind phase III trial has demonstrated the efficacy of capecitabine as part of a combination regimen in women with advanced breast cancer resistant to or failing anthracycline therapy. Capecitabine 1250 mg/m2 twice daily for 2 weeks of every 3-week cycle plus intravenous docetaxel 75 mg/m2 administered over a 1-hour infusion on day one of each cycle was superior to intravenous docetaxel 100 mg/m2 monotherapy on day one of each cycle in women with advanced breast cancer refractory to previous anthracycline therapy. The risks of disease progression and death were reduced by 35% (p = 0.0001) and 23% (p < 0.05) with capecitabine plus docetaxel. Median survival was longer with the combination than with docetaxel alone (14.5 vs 11.5 months, p < 0.05) and objective response rates were higher (42% vs 30%, p < 0.01). Smaller non-comparative trials demonstrated objective response rates of 52–63% in women pretreated with anthracyclines and/or taxanes who received therapy combining capecitabine with intravenous paclitaxel 175 mg/m2 every 3 weeks, intravenous vinorelbine 2530 mg/m2/week or (tumour overexpressing HER2) intravenous trastuzumab 2 mg/kg/week. First-line monotherapy with capecitabine 1255 mg/m2 twice daily for 2 weeks in every 3 resulted in an objective response rate of 30% in women aged ≥55 years versus 16% in those receiving intravenous cyclophosphamide 600 mg/m2 plus methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 (CMF) once every 3 weeks. Objective response rates of 49, 67 and 76% were seen with combination first-line therapy of capecitabine 825 to 1000 mg/m2 twice daily for 2 weeks in every 3 plus paclitaxel 175 mg/m2 once every 3 weeks, vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, or epirubicin plus docetaxel, both 75 mg/m2 every 3 weeks in noncomparative trials. Dosage reduction for adverse effects does not appear to compromise the efficacy of capecitabine. Two pharmacoeconomic studies have suggested that there may be cost savings associated with treatment of patients with locally advanced or metastatic breast cancer with capecitabine and docetaxel compared with docetaxel alone. Incremental cost-effectiveness ratios of $CAN4254 per life-year gained and $US5520 per quality-adjusted life year gained were reported. Adverse effects associated with administration of capecitabine monotherapy 1255 mg/m2 twice daily for 2 weeks in every 3, in six clinical trials in patients with breast or colorectal cancer (n = 570) and occurring at an incidence of ≥5%, were lymphopenia, anaemia, diarrhoea, hand-and-foot syndrome, nausea, fatigue, hyperbilirubinaemia, dermatitis and vomiting (all >25% incidence). Adverse effects graded level 4 included lymphopenia (10% incidence), hyperbilirubinaemia (3%), neutropenia (2%), diarrhoea (2%), dehydration (1%), thrombocytopenia (1%) and anaemia (1%), while those graded level 3 were lymphopenia (36%), gastrointestinal effects (27%), hyperbilirubinaemia (14%), hand-and-foot syndrome (13%), and fatigue, neutropenia, anorexia, dehydration, anaemia, dermatitis, headache, and thrombocytopenia (all ≤5%). Adverse effects were reported by most patients receiving oral capecitabine monotherapy or comparative agents in randomised nonblind clinical trials. Gastrointestinal effects and hand-and-foot syndrome occurred more often with oral capecitabine than with either intravenous paclitaxel or intravenous CMF, while neutropenic fever, arthralgia, pyrexia and myalgia were more common with paclitaxel, and nausea, stomatitis, alopecia and asthenia were more common with the CMF regimen. In patients receiving combination therapy, median delivered capecitabine and docetaxel doses were 77% and 87% of the planned doses. Doses were mainly reduced because of hand-and-foot syndrome, diarrhoea or stomatitis. Treatment-related adverse effects occurred in 98% of patients in the combination therapy group compared with 94% of patients receiving docetaxel monotherapy. The incidences of gastrointestinal adverse effects and hand-and-foot syndrome were higher among capecitabine plus docetaxel recipients, while neutropenic fever, arthralgia and pyrexia occurred more frequently among recipients of docetaxel monotherapy. In the US and Europe, capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Capecitabine monotherapy is indicated in patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or in those resistant to paclitaxel and for whom further anthracycline therapy is not indicated (US) or failing intensive chemotherapy (Europe). The recommended dosage is 1250 mg/m2 administered twice daily (equivalent to 2500 mg/m2/day) for 14 days followed by a 7-day rest. Capecitabine tablets should be taken within 30 minutes after a meal. Capecitabine is also approved for use in metastatic colorectal cancer. Capecitabine is contraindicated in patients with a known hypersensitivity to fluorouracil and in those with severe renal impairment; in Europe it is also contraindicated in those with severe hepatic impairment, dihydropyrimidine dehydrogenase deficiency, or severe leucopenia, neutropenia or thrombocytopenia. Dosages should be reduced in patients with moderate renal impairment. Patients taking coumarin anticoagulants or phenytoin concomitantly with capecitabine should be regularly monitored; in the US, there is a boxed warning recommending frequent monitoring with the use of capecitabine and coumarin anticoagulants. Concomitant use with allopurinol should be avoided. Capecitabine toxicity occurring during monotherapy can be managed with symptomatic treatment or dose modification.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (2) , 217-236
Capecitabine
Capecitabine is an orally administered prodrug of fluorouracil which is indicated in the US and Europe, in combination with docetaxel, for the treatment of patients with metastatic breast cancer failing anthracycline therapy, and as monotherapy for metastatic breast cancer resistant to paclitaxel and anthracycline therapy (US) or failing intensive chemotherapy (Europe). Capecitabine is also approved for use in metastatic colorectal cancer. Capecitabine is metabolically activated preferentially at the tumour site, and shows antineoplastic activity and synergy with other cytotoxic agents including cyclophosphamide or docetaxel in animal models. Bioavailability after oral administration is close to 100%. In patients with pretreated advanced breast cancer, capecitabine is effective as monotherapy and also in combination with other agents. Combination therapy with capecitabine 1250 mg/m2 twice daily for 2 weeks of every 3-week cycle plus intravenous docetaxel 75 mg/m2 on day one of each cycle was superior to intravenous monotherapy with docetaxel 100 mg/m2 on day one of each cycle. Capecitabine plus docetaxel significantly reduced the risks of disease progression and death by 35% (p = 0.0001) and 23% (p < 0.05), respectively, and significantly increased median survival (p < 0.05) and objective response rates (p < 0.01). Efficacy has also been demonstrated with capecitabine monotherapy and combination therapy in previously untreated patients in preliminary trials. The most common adverse effects occurring in patients receiving capecitabine monotherapy include lymphopenia, anaemia, diarrhoea, hand-and-foot syndrome, nausea, fatigue, hyperbilirubinaemia, dermatitis and vomiting (all >25% incidence). While gastrointestinal events and hand-and-foot syndrome occurred more often with capecitabine than with paclitaxel or a regimen of cyclophosphamide, methotrexate and fluorouracil (CMF), neutropenic fever, arthralgia, pyrexia and myalgia were more common with paclitaxel, and nausea, stomatitis, alopecia and asthenia were more common with CMF. The incidence of adverse effects and hospitalisation was similar in patients receiving capecitabine plus docetaxel and those receiving docetaxel monotherapy. In conclusion, capecitabine, an oral prodrug of fluorouracil which is activated preferentially at the tumour site, is an effective and convenient addition to the intravenous polychemotherapeutic treatment of advanced breast cancer in pretreated patients, and also has potential as a component of first-line combination regimens. Combined capecitabine plus docetaxel therapy resulted in similar rates of treatment-related adverse effects and hospitalisation to those seen with docetaxel monotherapy. Capecitabine is also effective as monotherapy in pretreated patients and phase II data for capecitabine as first-line monotherapy are also promising. While gastrointestinal effects and hand-and-foot syndrome occur often with capecitabine, the tolerability profile was comparatively favourable for other adverse effects (notably, neutropenia and alopecia). Capecitabine is an oral fluoropyrimidine which undergoes several metabolic changes in vivo, ultimately yielding fluorouracil. This occurs preferentially in tumour tissue and leads to subsequent formation of fluorodeoxyuridine mono-phosphate and fluorouridine triphosphate. Capecitabine demonstrates antineoplastic activity in human mammary tumour xenograft models, with synergistic effects when used in combination with other cytotoxic agents including cyclophosphamide and docetaxel. Pharmacokinetic studies with capecitabine have been performed in patients with solid tumours, many of which were colorectal but including some breast tumours. The oral bioavailability of capecitabine is nearly 100%. Maximum plasma concentrations and area under the plasma concentration-time curve (AUC) of capecitabine showed linear increases with dosage and were decreased when capecitabine was administered with food. Elimination of capecitabine is primarily renal; in patients with severe renal impairment, use of capecitabine is contraindicated. Capecitabine increased the AUC and decreased clearance of a single dose of warfarin. Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy therefore require frequent monitoring of their anticoagulant response. The pharmacokinetics of capecitabine are not significantly affected by paclitaxel or docetaxel. Oral capecitabine 1250 or 1255 mg/m2 twice daily for 2 weeks in every 3 has shown efficacy in prospective trials as monotherapy in patients with pretreated advanced breast cancer. Objective response rates with capecitabine monotherapy were 36% (vs a similar rate of 26% with intravenous paclitaxel 175 mg/m2 every 3 weeks) in women with disease resistant to or failing anthracycline therapy, 18 to 41% in those with disease resistant to or failing taxane therapy, and 43, 57 and 70% in those with relapsed disease after high-dose chemotherapy plus autologous stem cell support. A randomised nonblind phase III trial has demonstrated the efficacy of capecitabine as part of a combination regimen in women with advanced breast cancer resistant to or failing anthracycline therapy. Capecitabine 1250 mg/m2 twice daily for 2 weeks of every 3-week cycle plus intravenous docetaxel 75 mg/m2 administered over a 1-hour infusion on day one of each cycle was superior to intravenous docetaxel 100 mg/m2 monotherapy on day one of each cycle in women with advanced breast cancer refractory to previous anthracycline therapy. The risks of disease progression and death were reduced by 35% (p = 0.0001) and 23% (p < 0.05) with capecitabine plus docetaxel. Median survival was longer with the combination than with docetaxel alone (14.5 vs 11.5 months, p < 0.05) and objective response rates were higher (42% vs 30%, p < 0.01). Smaller non-comparative trials demonstrated objective response rates of 52–63% in women pretreated with anthracyclines and/or taxanes who received therapy combining capecitabine with intravenous paclitaxel 175 mg/m2 every 3 weeks, intravenous vinorelbine 2530 mg/m2/week or (tumour overexpressing HER2) intravenous trastuzumab 2 mg/kg/week. First-line monotherapy with capecitabine 1255 mg/m2 twice daily for 2 weeks in every 3 resulted in an objective response rate of 30% in women aged ≥55 years versus 16% in those receiving intravenous cyclophosphamide 600 mg/m2 plus methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 (CMF) once every 3 weeks. Objective response rates of 49, 67 and 76% were seen with combination first-line therapy of capecitabine 825 to 1000 mg/m2 twice daily for 2 weeks in every 3 plus paclitaxel 175 mg/m2 once every 3 weeks, vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, or epirubicin plus docetaxel, both 75 mg/m2 every 3 weeks in noncomparative trials. Dosage reduction for adverse effects does not appear to compromise the efficacy of capecitabine. Two pharmacoeconomic studies have suggested that there may be cost savings associated with treatment of patients with locally advanced or metastatic breast cancer with capecitabine and docetaxel compared with docetaxel alone. Incremental cost-effectiveness ratios of $CAN4254 per life-year gained and $US5520 per quality-adjusted life year gained were reported. Adverse effects associated with administration of capecitabine monotherapy 1255 mg/m2 twice daily for 2 weeks in every 3, in six clinical trials in patients with breast or colorectal cancer (n = 570) and occurring at an incidence of ≥5%, were lymphopenia, anaemia, diarrhoea, hand-and-foot syndrome, nausea, fatigue, hyperbilirubinaemia, dermatitis and vomiting (all >25% incidence). Adverse effects graded level 4 included lymphopenia (10% incidence), hyperbilirubinaemia (3%), neutropenia (2%), diarrhoea (2%), dehydration (1%), thrombocytopenia (1%) and anaemia (1%), while those graded level 3 were lymphopenia (36%), gastrointestinal effects (27%), hyperbilirubinaemia (14%), hand-and-foot syndrome (13%), and fatigue, neutropenia, anorexia, dehydration, anaemia, dermatitis, headache, and thrombocytopenia (all ≤5%). Adverse effects were reported by most patients receiving oral capecitabine monotherapy or comparative agents in randomised nonblind clinical trials. Gastrointestinal effects and hand-and-foot syndrome occurred more often with oral capecitabine than with either intravenous paclitaxel or intravenous CMF, while neutropenic fever, arthralgia, pyrexia and myalgia were more common with paclitaxel, and nausea, stomatitis, alopecia and asthenia were more common with the CMF regimen. In patients receiving combination therapy, median delivered capecitabine and docetaxel doses were 77% and 87% of the planned doses. Doses were mainly reduced because of hand-and-foot syndrome, diarrhoea or stomatitis. Treatment-related adverse effects occurred in 98% of patients in the combination therapy group compared with 94% of patients receiving docetaxel monotherapy. The incidences of gastrointestinal adverse effects and hand-and-foot syndrome were higher among capecitabine plus docetaxel recipients, while neutropenic fever, arthralgia and pyrexia occurred more frequently among recipients of docetaxel monotherapy. In the US and Europe, capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Capecitabine monotherapy is indicated in patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or in those resistant to paclitaxel and for whom further anthracycline therapy is not indicated (US) or failing intensive chemotherapy (Europe). The recommended dosage is 1250 mg/m2 administered twice daily (equivalent to 2500 mg/m2/day) for 14 days followed by a 7-day rest. Capecitabine tablets should be taken within 30 minutes after a meal. Capecitabine is also approved for use in metastatic colorectal cancer. Capecitabine is contraindicated in patients with a known hypersensitivity to fluorouracil and in those with severe renal impairment; in Europe it is also contraindicated in those with severe hepatic impairment, dihydropyrimidine dehydrogenase deficiency, or severe leucopenia, neutropenia or thrombocytopenia. Dosages should be reduced in patients with moderate renal impairment. Patients taking coumarin anticoagulants or phenytoin concomitantly with capecitabine should be regularly monitored; in the US, there is a boxed warning recommending frequent monitoring with the use of capecitabine and coumarin anticoagulants. Concomitant use with allopurinol should be avoided. Capecitabine toxicity occurring during monotherapy can be managed with symptomatic treatment or dose modification.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (11) , 1121-1163
Abciximab
Abciximab (Reopro®) is an antibody fragment that dose-dependently inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein (GP) IIb/IIIa, vitronectin and Mac-1 receptors. Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) showed greater efficacy than tirofiban in reducing the 30-day composite endpoint of death, nonfatal myocardial infarction (MI) or urgent target-vessel revascularisation in the randomised, double-blind TARGET study in patients scheduled for stent placement. In addition, the beneficial effects of treatment with abciximab previously observed in the randomised, multicentre, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischaemic complications relative to placebo consistently observed across a range of subgroups including age, sex, bodyweight and indication for revascularisation. The incidence of the composite endpoint was reduced in patients presenting with acute MI of 80% of GP IIb/IIIa receptors and produces the maximum antiplatelet effect (>80% inhibition of ADP-induced platelet aggregation) at 10 minutes after treatment initiation. Continuous infusion (0.125 μg/kg/min or 10 μg/ min) after the bolus maintains near maximal platelet inhibition. However, marked interindividual variability has been observed in the degree of platelet inhibition in patients undergoing revascularisation. Ex vivo, administration of abciximab (0.25 mg/kg bolus then 10 μg/min for 12 hours) to patients undergoing percutaneous coronary revascularisation has shown generally equivalent inhibition of platelet aggregation in response to ADP or thrombin receptor-activating peptide (TRAP) as tirofiban or eptifibatide, although dosage regimens of tirofiban and eptifibatide varied between some studies. Platelet aggregation was significantly increased relative to baseline following fibrinolytic therapy with either alteplase or reteplase in patients with acute myocardial infarction (MI; n = 51) enrolled in the dose-finding TIMI-14 trial, but no significant differences in platelet aggregation at 90 minutes or 24 hours were evident between patients who received abciximab (0.25 mg/kg bolus) with either reduced doses of reteplase (a 5U bolus and either 5 or 10U bolus) or alteplase (dose range 35 to 65mg); all patients receiving combination abciximab/fibrinolytic therapy achieved >80% inhibition of platelet aggregation at 90 minutes which was sustained for ≥24 hours after initiation of abciximab treatment. The addition of ticlopidine to treatment maintained the platelet inhibition achieved with abciximab therapy during the first 24 hours. In addition to inhibition of platelet aggregation, abciximab has shown potentially antithrombotic effects which are independent of heparin administration. Abciximab inhibits platelet-dependent thrombin generation, most likely through blockade of both GP IIb/IIIa and vitronectin receptors. Blockade of vitronectin receptors prevents smooth muscle cell adhesion and migration, thus reducing intimal proliferation. Moreover, abciximab may inhibit activated Mac-1 receptors, thus reducing monocyte and polymorphonuclear leucocyte recruitment at the site vascular injury. Abciximab binds rapidly to platelets after administration and has an initial half-life of > 10 minutes and a second phase half-life of about 30 minutes. Platelet function generally recovers within 48 hours, although platelet-bound abciximab is still detectable 15 days or more after administration in a platelet-bound state. in General Patient Populations: Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) has been investigated as an adjunct to aspirin and heparin in patients undergoing percutaneous coronary intervention. Large well designed studies have shown abciximab prevents acute ischaemic complications (death, MI or urgent revascularisation). Abciximab demonstrated greater efficacy at 30 days than tirofiban treatment (10 μg/kg bolus then 0.15 μg/kg/min IV infusion for 18 to 24 hours) in the randomised, double-blind, multicentre TARGET study in patients scheduled for stent placement. At 30 days, the composite endpoint of death, nonfatal MI or urgent target-vessel revascularisation occurred in significantly fewer patients who received abciximab than received tirofiban (6.0 and 7.6%, respectively), mainly because of a greater number of MI events in patients treated with tirofiban (5.4 vs 6.9%). p ]The beneficial effects of treatment with abciximab previously observed in the randomised, multicentre, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischaemic complications relative to placebo which was consistently observed across a range of subgroups (including age, sex, bodyweight and indication for evascularisation). Factors which were significantly and independently associated with improved survival at 1 year in multivariate analysis in EPISTENT were use of abciximab in combination with stenting (versus placebo and stenting alone), and preprocedural percentage diameter stenosis, whereas worse survival was associated with previous congestive heart failure, type 1 diabetes mellitus, age >70 years and postprocedural TIMI grade 0 flow. Nonetheless, abciximab has demonstrated efficacy, reducing the composite endpoint of death, MI or target-vessel revascularisation, in a prospectively defined subset of patients with diabetes mellitus undergoing percutaneous coronary intervention in the EPISTENT study. In Acute Myocardial Infarction: Five randomised comparative studies (ADMIRAL, CADILLAC, STOPAMI, STOPAMI-2, and ISAR-2) have investigated the use of abciximab in combination with stent placement in patients with acute MI. Both STOPAMI and ADMIRAL studies reported that patients receiving abciximab plus stent showed a significantly reduced composite endpoint compared to either fibrinolytic therapy or stent alone at 30 days. In STOPAMI-2 atients receiving abciximab plus stent showed a greater myocardial salvage index than those receiving abciximab plus alteplase. Results of the CADILLAC study suggest that stent plus abciximab, angioplasty plus abciximab and stent alone each leads to significantly better outcomes at 30 days compared to angioplasty alone. Patients receiving stent plus abciximab showed a significantly lower rate of revascularisation than those receiving angioplasty either alone or in combination with abciximab. In the ADMIRAL study, blood flow was greater in patients who received abciximab than in placebo recipients immediately following revascularisation (TIMI grade 3 flow achieved in 95.1% vs 86.7% of patients; p = 0.04) and at 6 months with (94.3% vs 82.8%). Recent large randomised, nonblind, multicentre studies (ASSENT-3 and GUSTO-V) have shown higher efficacy with abciximab in combination with either a reduced dose of tenecteplase or reteplase than the full-dose fibrinolytic drug alone. The effect of abciximab in combination with fibrinolytic therapy (either alteplase, streptokinase or reteplase) on reperfusion after acute MI was investigated in the TIMI-14 and SPEED trials. More patients who received abciximab in combination with fibrinolytic therapy in TIMI-14 and SPEED achieved TIMI grade 3 flow rates at 60 and 90 minutes than those who received abciximab alone. In TIMI-14, at both 60 and 90 minutes TIMI grade 3 flow rates were significantly greater in patients receiving abciximab plus fibrinolytic therapy than than in those receiving full-dose fibrinolytic alone (p = 0.0009 and 0.02, respectively). In the multicentre SPEED study, the percentage of patients achieving TIMI grade 3 flow rates 60 to 90 minutes after reperfusion treatment was greatest in patients who received two 5U boluses reteplase plus abciximab (62%). Pooled Analyses: Pooled analysis of large, randomised, placebo-controlled trials involving abciximab (>9000 patients) showed a decrease in mortality of approximately 30% compared with placebo at 1 year; mortality was also reduced to a similar extent with either angioplasty or stenting (both approximately 30%). Analyses from the EPIC, EPILOG and EPISTENT trials showed that the overall treatment benefit (as indicated by 30-day and 6-month ischaemic outcomes) with abciximab was observed irrespective of sex or smoking status. In meta-analyses of prospective, randomised placebo-controlled trials GP IIb/ IIIa antagonists reduced the need for urgent revascularisation but had no effect on mortality compared to placebo. Abciximab but not eptifibatide or tirofiban significantly reduced the incidence of acute MI compared to placebo. In Patients Without Early Revascularisation: In the randomised, multicentre GUSTO IV-ACS study, no differences were apparent between groups of patients with ACS who were not scheduled to undergo early revascularisation (within 12 hours of end of infusion) who had received abciximab (bolus and either 24- or 48-hour infusion) in addition to aspirin and heparin in any of the ischaemic endpoints at either 7 or 30 days (primary endpoint) compared with placebo. The most common adverse events associated with the use of abciximab are bleeding complications and thrombocytopenia, although the risk of major bleeding can be limited through careful selection of patients, use of a low-dose, bodyweight-adjusted regimen of heparin, discontinuation of heparin immediately following revascularisation, early removal of the vascular sheath and femoral artery access site care. In recent large, randomised clinical trials (ADMIRAL, GUSTO IV-ACS and TARGET), the incidence of major bleeding with a standard dose of abciximab (0.6–0.7% of patients) was similar to that seen with placebo (0% and 0.3%) and tirofiban (0.9%), although extension of the abciximab infusion to 48 hours significantly increased the incidence of major bleeding complications relative to placebo in one arm of the GUSTO IV-ACS trial (1% vs 0.3%). Rates of minor bleeding were significantly greater (3–12.1%) than with either placebo (2% and 3.3%) or tirofiban (2.8%). Thrombocytopenia (platelet count 9/L) developed in 2.4–7% of abciximab-treated patients (the higher value was recorded in patients receiving a 48 hour infusion of abciximab in GUSTO IV-ACS) compared with ≈1% of placebo and 0.5% of tirofiban recipients in the ADMIRAL, GUSTO IV-ACS and TARGET clinical trials. Severe thrombocytopenia (platelet count 9/L) was observed in 0.9–2% of patients who received abciximab, 0.04% and 1.3% of placebo recipients and 0.1% of tirofiban recipients. 2.1% of patients treated with abciximab were identified as having pseudothrombocytopenia in pooled data from the CAPTURE, EPIC, EPILOG and EPISTENT trials compared with 0.6% of patients who received placebo. In the ASSENT-3 trial, rates of major and minor bleeding were significantly higher in patients receiving abciximab plus tenecteplase than in those receiving tenecteplase alone or plus enoxaparin. Similarly, in GUSTO-V rates of major and minor bleeding were significantly higher in patients receiving abciximab plus reteplase than in those receiving reteplase alone. In both studies, the rates of intracranial haemorrhage were similar for each treatment group. No cases of anaphylactic, allergic or other hypersensitivity reactions have been reported in 500 patients enrolled in the ReoPro Readministration Registry. Cumulative treatment costs from a prospectively defined subset of patients in the US who participated in the EPISTENT study at 1 year were significantly higher in both the stent plus abciximab (by $US932) and angioplasty plus abciximab ($US581) groups than in the stent plus placebo group, primarily because of the acquisition cost of abciximab. The addition of abciximab to stenting also significantly increased the estimated mean costs per patient after 6 months’ treatment when results of the EPISTENT trial were extrapolated to a European setting based on an economic evaluation from the BElgian NEtherlands Stent (BENESTENT)-II study. Cost savings associated with abciximab in a prospectively defined economic substudy of EPILOG were for the most part attributed to a reduced requirement for repeat revascularisation, bailout stenting and shorter hospital stays. Over a 6-month follow-up period, hospitalisation costs remained increased in the abciximab groups because of an increase in the number of patients undergoing nonurgent revascularisation. Increased costs in the abciximab group were primarily because of drug acquisition costs. Two nonrandomised studies (based in the US and Netherlands) showed a reduced incidence of ischaemic complications with abciximab and stenting; however, overall treatment costs were similar or increased in these patients compared with those who underwent only percutaneous coronary intervention. Among lower risk patients undergoing elective percutaneous coronary revascularisation, abciximab has been associated with higher total in-hospital and 6-month medical costs than eptifibatide in the prospective PRICE cost analysis study. Abciximab appeared most cost beneficial in high-risk patients in a retrospective cost analysis; the estimated cost to prevent one event was $US39 201 compared with $US74 047 for tirofiban. Patients treated with abciximab spent fewer days in hospital than patients who received either tirofiban or eptifibatide according to a retrospective analysis. An incremental cost of $US932, or cost-effectiveness ratio of $US6213 per added life-year, was seen in the stent plus abciximab group compared with stent and placebo in EPISTENT. Patients who received abciximab plus stent had an incremental cost of $US581 and a cost-effectiveness ratio of $US5291 per added life-year in comparison with the abciximab and angioplasty group. One Italian-based analysis has evaluated the cost effectiveness of abciximab based on 6-month results from the EPILOG, EPIC (not including patients who received only abciximab bolus) and CAPTURE studies. Cost-effectiveness ratios for patients in the abciximab and placebo groups were L16.6 and L15.4 million Lire per event-free patient (approximately $US7543 and $US6998; 2002 values), resulting in an incremental cost-effectiveness ratio of L34.3 ($US15 587) per event avoided at 6 months after intervention. The recommended dosage of abciximab is a 0.25 mg/kg IV bolus administered 10 to 60 minutes before the start of percutaneous coronary intervention, followed by a continuous IV infusion of 0.125 μg/kg/min (up to a maximum of 10 μg/min) for 12 hours. For patients with refractory unstable angina pectoris in whom percutaneous coronary revascularisation is planned within 24 hours, the recommended dosage is an IV bolus of 0.25 mg/kg followed by an infusion of 10 μg/min for 18 to 24 hours before the procedure and finishing 1 hour (US recommendation) or 12 hours (UK recommendation) after the procedure. Abciximab should be used in combination with aspirin and heparin. Abciximab is contraindicated in patients at high risk for bleeding complications or in whom bleeding complications would have serious consequences, those requiring IV dextran and those with known hypersensitivity to the drug. Haemostatic parameters should be measured before administration. Caution is required in patients receiving other drugs that affect haemostasis. Infusion of abciximab and heparin should be stopped if uncontrollable serious bleeding occurs or if emergency surgery is required. To reduce the risk of bleeding, careful femoral artery access site care, use of a low-dose, bodyweight-adjusted regimen of heparin, discontinuation of heparin immediately after the procedure, early removal of the arterial sheath and careful patient management are recommended. Platelet counts should be monitored before and during treatment. If the platelet count decreases by ≥25% and to 9/L, abciximab should be discontinued and appropriate treatment initiated.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (11) , 1121-1163
Abciximab
Abciximab (Reopro®) is an antibody fragment that dose-dependently inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein (GP) IIb/IIIa, vitronectin and Mac-1 receptors. Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) showed greater efficacy than tirofiban in reducing the 30-day composite endpoint of death, nonfatal myocardial infarction (MI) or urgent target-vessel revascularisation in the randomised, double-blind TARGET study in patients scheduled for stent placement. In addition, the beneficial effects of treatment with abciximab previously observed in the randomised, multicentre, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischaemic complications relative to placebo consistently observed across a range of subgroups including age, sex, bodyweight and indication for revascularisation. The incidence of the composite endpoint was reduced in patients presenting with acute MI of 80% of GP IIb/IIIa receptors and produces the maximum antiplatelet effect (>80% inhibition of ADP-induced platelet aggregation) at 10 minutes after treatment initiation. Continuous infusion (0.125 μg/kg/min or 10 μg/ min) after the bolus maintains near maximal platelet inhibition. However, marked interindividual variability has been observed in the degree of platelet inhibition in patients undergoing revascularisation. Ex vivo, administration of abciximab (0.25 mg/kg bolus then 10 μg/min for 12 hours) to patients undergoing percutaneous coronary revascularisation has shown generally equivalent inhibition of platelet aggregation in response to ADP or thrombin receptor-activating peptide (TRAP) as tirofiban or eptifibatide, although dosage regimens of tirofiban and eptifibatide varied between some studies. Platelet aggregation was significantly increased relative to baseline following fibrinolytic therapy with either alteplase or reteplase in patients with acute myocardial infarction (MI; n = 51) enrolled in the dose-finding TIMI-14 trial, but no significant differences in platelet aggregation at 90 minutes or 24 hours were evident between patients who received abciximab (0.25 mg/kg bolus) with either reduced doses of reteplase (a 5U bolus and either 5 or 10U bolus) or alteplase (dose range 35 to 65mg); all patients receiving combination abciximab/fibrinolytic therapy achieved >80% inhibition of platelet aggregation at 90 minutes which was sustained for ≥24 hours after initiation of abciximab treatment. The addition of ticlopidine to treatment maintained the platelet inhibition achieved with abciximab therapy during the first 24 hours. In addition to inhibition of platelet aggregation, abciximab has shown potentially antithrombotic effects which are independent of heparin administration. Abciximab inhibits platelet-dependent thrombin generation, most likely through blockade of both GP IIb/IIIa and vitronectin receptors. Blockade of vitronectin receptors prevents smooth muscle cell adhesion and migration, thus reducing intimal proliferation. Moreover, abciximab may inhibit activated Mac-1 receptors, thus reducing monocyte and polymorphonuclear leucocyte recruitment at the site vascular injury. Abciximab binds rapidly to platelets after administration and has an initial half-life of > 10 minutes and a second phase half-life of about 30 minutes. Platelet function generally recovers within 48 hours, although platelet-bound abciximab is still detectable 15 days or more after administration in a platelet-bound state. in General Patient Populations: Abciximab (0.25 mg/kg bolus plus infusion of 0.125 μg/kg/min for 12 hours) has been investigated as an adjunct to aspirin and heparin in patients undergoing percutaneous coronary intervention. Large well designed studies have shown abciximab prevents acute ischaemic complications (death, MI or urgent revascularisation). Abciximab demonstrated greater efficacy at 30 days than tirofiban treatment (10 μg/kg bolus then 0.15 μg/kg/min IV infusion for 18 to 24 hours) in the randomised, double-blind, multicentre TARGET study in patients scheduled for stent placement. At 30 days, the composite endpoint of death, nonfatal MI or urgent target-vessel revascularisation occurred in significantly fewer patients who received abciximab than received tirofiban (6.0 and 7.6%, respectively), mainly because of a greater number of MI events in patients treated with tirofiban (5.4 vs 6.9%). p ]The beneficial effects of treatment with abciximab previously observed in the randomised, multicentre, placebo-controlled EPILOG and EPISTENT studies have been maintained to 1 year, with a significantly reduced incidence of ischaemic complications relative to placebo which was consistently observed across a range of subgroups (including age, sex, bodyweight and indication for evascularisation). Factors which were significantly and independently associated with improved survival at 1 year in multivariate analysis in EPISTENT were use of abciximab in combination with stenting (versus placebo and stenting alone), and preprocedural percentage diameter stenosis, whereas worse survival was associated with previous congestive heart failure, type 1 diabetes mellitus, age >70 years and postprocedural TIMI grade 0 flow. Nonetheless, abciximab has demonstrated efficacy, reducing the composite endpoint of death, MI or target-vessel revascularisation, in a prospectively defined subset of patients with diabetes mellitus undergoing percutaneous coronary intervention in the EPISTENT study. In Acute Myocardial Infarction: Five randomised comparative studies (ADMIRAL, CADILLAC, STOPAMI, STOPAMI-2, and ISAR-2) have investigated the use of abciximab in combination with stent placement in patients with acute MI. Both STOPAMI and ADMIRAL studies reported that patients receiving abciximab plus stent showed a significantly reduced composite endpoint compared to either fibrinolytic therapy or stent alone at 30 days. In STOPAMI-2 atients receiving abciximab plus stent showed a greater myocardial salvage index than those receiving abciximab plus alteplase. Results of the CADILLAC study suggest that stent plus abciximab, angioplasty plus abciximab and stent alone each leads to significantly better outcomes at 30 days compared to angioplasty alone. Patients receiving stent plus abciximab showed a significantly lower rate of revascularisation than those receiving angioplasty either alone or in combination with abciximab. In the ADMIRAL study, blood flow was greater in patients who received abciximab than in placebo recipients immediately following revascularisation (TIMI grade 3 flow achieved in 95.1% vs 86.7% of patients; p = 0.04) and at 6 months with (94.3% vs 82.8%). Recent large randomised, nonblind, multicentre studies (ASSENT-3 and GUSTO-V) have shown higher efficacy with abciximab in combination with either a reduced dose of tenecteplase or reteplase than the full-dose fibrinolytic drug alone. The effect of abciximab in combination with fibrinolytic therapy (either alteplase, streptokinase or reteplase) on reperfusion after acute MI was investigated in the TIMI-14 and SPEED trials. More patients who received abciximab in combination with fibrinolytic therapy in TIMI-14 and SPEED achieved TIMI grade 3 flow rates at 60 and 90 minutes than those who received abciximab alone. In TIMI-14, at both 60 and 90 minutes TIMI grade 3 flow rates were significantly greater in patients receiving abciximab plus fibrinolytic therapy than than in those receiving full-dose fibrinolytic alone (p = 0.0009 and 0.02, respectively). In the multicentre SPEED study, the percentage of patients achieving TIMI grade 3 flow rates 60 to 90 minutes after reperfusion treatment was greatest in patients who received two 5U boluses reteplase plus abciximab (62%). Pooled Analyses: Pooled analysis of large, randomised, placebo-controlled trials involving abciximab (>9000 patients) showed a decrease in mortality of approximately 30% compared with placebo at 1 year; mortality was also reduced to a similar extent with either angioplasty or stenting (both approximately 30%). Analyses from the EPIC, EPILOG and EPISTENT trials showed that the overall treatment benefit (as indicated by 30-day and 6-month ischaemic outcomes) with abciximab was observed irrespective of sex or smoking status. In meta-analyses of prospective, randomised placebo-controlled trials GP IIb/ IIIa antagonists reduced the need for urgent revascularisation but had no effect on mortality compared to placebo. Abciximab but not eptifibatide or tirofiban significantly reduced the incidence of acute MI compared to placebo. In Patients Without Early Revascularisation: In the randomised, multicentre GUSTO IV-ACS study, no differences were apparent between groups of patients with ACS who were not scheduled to undergo early revascularisation (within 12 hours of end of infusion) who had received abciximab (bolus and either 24- or 48-hour infusion) in addition to aspirin and heparin in any of the ischaemic endpoints at either 7 or 30 days (primary endpoint) compared with placebo. The most common adverse events associated with the use of abciximab are bleeding complications and thrombocytopenia, although the risk of major bleeding can be limited through careful selection of patients, use of a low-dose, bodyweight-adjusted regimen of heparin, discontinuation of heparin immediately following revascularisation, early removal of the vascular sheath and femoral artery access site care. In recent large, randomised clinical trials (ADMIRAL, GUSTO IV-ACS and TARGET), the incidence of major bleeding with a standard dose of abciximab (0.6–0.7% of patients) was similar to that seen with placebo (0% and 0.3%) and tirofiban (0.9%), although extension of the abciximab infusion to 48 hours significantly increased the incidence of major bleeding complications relative to placebo in one arm of the GUSTO IV-ACS trial (1% vs 0.3%). Rates of minor bleeding were significantly greater (3–12.1%) than with either placebo (2% and 3.3%) or tirofiban (2.8%). Thrombocytopenia (platelet count 9/L) developed in 2.4–7% of abciximab-treated patients (the higher value was recorded in patients receiving a 48 hour infusion of abciximab in GUSTO IV-ACS) compared with ≈1% of placebo and 0.5% of tirofiban recipients in the ADMIRAL, GUSTO IV-ACS and TARGET clinical trials. Severe thrombocytopenia (platelet count 9/L) was observed in 0.9–2% of patients who received abciximab, 0.04% and 1.3% of placebo recipients and 0.1% of tirofiban recipients. 2.1% of patients treated with abciximab were identified as having pseudothrombocytopenia in pooled data from the CAPTURE, EPIC, EPILOG and EPISTENT trials compared with 0.6% of patients who received placebo. In the ASSENT-3 trial, rates of major and minor bleeding were significantly higher in patients receiving abciximab plus tenecteplase than in those receiving tenecteplase alone or plus enoxaparin. Similarly, in GUSTO-V rates of major and minor bleeding were significantly higher in patients receiving abciximab plus reteplase than in those receiving reteplase alone. In both studies, the rates of intracranial haemorrhage were similar for each treatment group. No cases of anaphylactic, allergic or other hypersensitivity reactions have been reported in 500 patients enrolled in the ReoPro Readministration Registry. Cumulative treatment costs from a prospectively defined subset of patients in the US who participated in the EPISTENT study at 1 year were significantly higher in both the stent plus abciximab (by $US932) and angioplasty plus abciximab ($US581) groups than in the stent plus placebo group, primarily because of the acquisition cost of abciximab. The addition of abciximab to stenting also significantly increased the estimated mean costs per patient after 6 months’ treatment when results of the EPISTENT trial were extrapolated to a European setting based on an economic evaluation from the BElgian NEtherlands Stent (BENESTENT)-II study. Cost savings associated with abciximab in a prospectively defined economic substudy of EPILOG were for the most part attributed to a reduced requirement for repeat revascularisation, bailout stenting and shorter hospital stays. Over a 6-month follow-up period, hospitalisation costs remained increased in the abciximab groups because of an increase in the number of patients undergoing nonurgent revascularisation. Increased costs in the abciximab group were primarily because of drug acquisition costs. Two nonrandomised studies (based in the US and Netherlands) showed a reduced incidence of ischaemic complications with abciximab and stenting; however, overall treatment costs were similar or increased in these patients compared with those who underwent only percutaneous coronary intervention. Among lower risk patients undergoing elective percutaneous coronary revascularisation, abciximab has been associated with higher total in-hospital and 6-month medical costs than eptifibatide in the prospective PRICE cost analysis study. Abciximab appeared most cost beneficial in high-risk patients in a retrospective cost analysis; the estimated cost to prevent one event was $US39 201 compared with $US74 047 for tirofiban. Patients treated with abciximab spent fewer days in hospital than patients who received either tirofiban or eptifibatide according to a retrospective analysis. An incremental cost of $US932, or cost-effectiveness ratio of $US6213 per added life-year, was seen in the stent plus abciximab group compared with stent and placebo in EPISTENT. Patients who received abciximab plus stent had an incremental cost of $US581 and a cost-effectiveness ratio of $US5291 per added life-year in comparison with the abciximab and angioplasty group. One Italian-based analysis has evaluated the cost effectiveness of abciximab based on 6-month results from the EPILOG, EPIC (not including patients who received only abciximab bolus) and CAPTURE studies. Cost-effectiveness ratios for patients in the abciximab and placebo groups were L16.6 and L15.4 million Lire per event-free patient (approximately $US7543 and $US6998; 2002 values), resulting in an incremental cost-effectiveness ratio of L34.3 ($US15 587) per event avoided at 6 months after intervention. The recommended dosage of abciximab is a 0.25 mg/kg IV bolus administered 10 to 60 minutes before the start of percutaneous coronary intervention, followed by a continuous IV infusion of 0.125 μg/kg/min (up to a maximum of 10 μg/min) for 12 hours. For patients with refractory unstable angina pectoris in whom percutaneous coronary revascularisation is planned within 24 hours, the recommended dosage is an IV bolus of 0.25 mg/kg followed by an infusion of 10 μg/min for 18 to 24 hours before the procedure and finishing 1 hour (US recommendation) or 12 hours (UK recommendation) after the procedure. Abciximab should be used in combination with aspirin and heparin. Abciximab is contraindicated in patients at high risk for bleeding complications or in whom bleeding complications would have serious consequences, those requiring IV dextran and those with known hypersensitivity to the drug. Haemostatic parameters should be measured before administration. Caution is required in patients receiving other drugs that affect haemostasis. Infusion of abciximab and heparin should be stopped if uncontrollable serious bleeding occurs or if emergency surgery is required. To reduce the risk of bleeding, careful femoral artery access site care, use of a low-dose, bodyweight-adjusted regimen of heparin, discontinuation of heparin immediately after the procedure, early removal of the arterial sheath and careful patient management are recommended. Platelet counts should be monitored before and during treatment. If the platelet count decreases by ≥25% and to 9/L, abciximab should be discontinued and appropriate treatment initiated.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (19) , 2029-2050
Lamotrigine
Lamotrigine (Lamictal®), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder. The mechanism of action of the drug in patients with bipolar disorder may be related to the inhibition of sodium and calcium channels in presynaptic neurons and subsequent stabilisation of the neuronal membrane. Lamotrigine monotherapy significantly delayed time to intervention with additional pharmacotherapy or electroconvulsive therapy for any new mood episode (mania, hypomania, depression and mixed episodes), compared with placebo, in two large, randomised, double-blind trials of 18 months’ duration. Additionally, lamotrigine was significantly superior to placebo at prolonging time to intervention for depression. These effects of lamotrigine were demonstrated in both recently manic/hypomanic and recently depressed patients. Lamotrigine showed efficacy in delaying manic/hypomanic episodes in pooled data only, although lithium was superior to lamotrigine on this measure. Two of four double-blind, short-term studies have shown lamotrigine to be more effective than placebo in the treatment of patients with treatment-refractory bipolar disorder or those with bipolar depression. Lamotrigine has not demonstrated efficacy in the treatment of acute mania. Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia. Incidences of diarrhoea and tremor were significantly lower in lamotrigine-than in lithium-treated patients. The incidence of serious rash with lamotrigine treatment was 0.1% in all studies of bipolar disorder and included one case of mild Stevens-Johnson syndrome. Lamotrigine did not appear to cause bodyweight gain. The dosage of lamotrigine is titrated over a 6-week period to 200 mg/day to minimise the incidence of serious rash. Adjustments to the initial and target dosages are required if coadministered with valproate semisodium or carbamazepine. Conclusion: Lamotrigine has been shown to be an effective maintenance therapy for patients with bipolar I disorder, significantly delaying time to intervention for any mood episode. Additionally, lamotrigine significantly delayed time to intervention for a depressive episode and showed limited efficacy in delaying time to intervention for a manic/hypomanic episode, compared with placebo. Although not approved for the short-term treatment of mood episodes, lamotrigine has shown efficacy in the acute treatment of patients with bipolar depression but has not demonstrated efficacy in the treatment of acute mania. Lamotrigine is generally well tolerated, does not appear to cause bodyweight gain and, unlike lithium, generally does not require monitoring of serum levels. Lamotrigine is a phenyltriazine derivative. The mechanism of action of the drug in the treatment of patients with bipolar disorder is not fully understood, but may be related to the inhibition of sodium and calcium channels in presynaptic neurons and subsequent stabilisation of the neuronal membrane. In addition, lamotrigine has demonstrated neuroprotective effects in animal models. Lamotrigine lacks appreciable in vitro affinity for dopaminergic, adrenergic, muscarinic, opioid and adenosine receptors at clinically relevant concentrations, but binds weakly to serotonin 5HT3 receptors. It also down-regulates cortical 5HT1A receptor-mediated adenyl cyclase responses in an animal model. Normal synaptic conduction is unaffected by lamotrigine, which suppresses abnormal (sustained repetitive) firing of sodium-dependent action potentials in animal models. Early studies in patients with epilepsy who received lamotrigine indicated a propensity for improved mood, which led to controlled clinical trials in patients with bipolar disorder. Lamotrigine has minimal effects on psychomotor, cognitive and memory function and appears not to be associated with sedative effects or bodyweight gain. Oral lamotrigine is readily bioavailable (98%), and undergoes minimal first-pass metabolism. Absorption of lamotrigine is unaffected by food. Linear pharmacokinetics show peak lamotrigine concentrations occurring 1–3 hours after a dose. Mean protein binding is 55–68% and the drug is widely distributed to all organs and tissues, including brain tissue. It also crosses the placenta and is found in the fetus and in breast milk. Lamotrigine is extensively metabolised in the liver, predominantly via N-glucuronidation (the rate-limiting step in elimination of the drug). Clearance is 1.6–2.6 L/h and the mean plasma elimination half-life is 25–35 hours. Lamotrigine pharmacokinetics appear not to be significantly altered by many commonly used psychotropic agents, nor does lamotrigine alter the pharmacokinetics of lithium. However, enzyme-inhibiting drugs (e.g. valproate semi-sodium) increase lamotrigine plasma concentrations and enzyme-inducing drugs (e.g. carbamazepine) decrease lamotrigine concentrations. Lamotrigine appears not to have clinically significant reciprocal effects on the pharmacokinetics of these drugs. Lamotrigine has been shown to be an effective maintenance treatment in patients with bipolar I disorder who have had a recent depressive or manic/hypomanic episode. Data from two placebo-controlled, double-blind, 18-month comparative studies showed that lamotrigine (100–400 mg/day) or lithium (dose titrated to a serum level of 0.8–1.1 mEq/L) each significantly delayed the time to intervention with additional pharmacotherapy or electroconvulsive therapy for an emerging mood episode compared with placebo (p < 0.05 for lamotrigine vs placebo and for lithium vs placebo in both studies). In addition, both studies showed that lamotrigine, but not lithium, was significantly superior to placebo at prolonging time to intervention for a depressive mood episode. Similarly lithium, but not lamotrigine, was significantly better than placebo at delaying time to intervention for an emerging manic/hypomanic episode. However, in pooled data lamotrigine also significantly delayed time to intervention for a manic/hypomanic episode, although lithium was superior to lamotrigine on this measure. Lamotrigine was shown to be more effective than placebo in the treatment of patients with treatment-refractory bipolar disorder or those with bipolar depression in two of four double-blind short-term studies. Lamotrigine has not demonstrated efficacy in the treatment of acute mania. Lamotrigine 100–400 mg/day as monotherapy was generally well tolerated in two maintenance trials in patients with bipolar I disorder, with a similar adverse event profile to that of placebo. The most common adverse events were headache (19%), nausea (14%), infection (13%) and insomnia (10%). Significantly fewer lamotrigine recipients, compared with those receiving lithium, reported diarrhoea and tremor. The incidence of adverse events was similar in patients who received lamotrigine dosages of 50 mg/day compared with those who received 200 mg/day. Maintenance therapy with lamotrigine did not appear to increase bodyweight after 52 weeks’ treatment. Obese patients (body mass index ≥30 kg/m2) receiving lamotrigine lost an average 2.96kg, whereas those who received lithium or placebo gained 3.3 and 1.46kg, respectively. In a meta-analysis of eight randomised, double-blind, placebo-controlled trials in patients with bipolar disorder, serious adverse events occurred at a similar rate in patients receiving lamotrigine (8%), lithium (8%) and placebo (7%). Induction of mania was the most common serious adverse event and occurred in 3% of patients in each treatment group. The incidence of suicide per year in the meta-analysis was similar between patients receiving lamotrigine and placebo (0.7% vs 0.6%) while no suicides occurred among lithium recipients. Suicide attempts occurred at a similar rate per year in both lamotrigine (1.8%) and placebo (1.1%) recipients. Sexual problems were reported in <1% of patients receiving lamotrigine. Three of 2272 (0.1%) patients receiving lamotrigine in all controlled and uncontrolled bipolar disorder studies developed a serious rash, including one case of mild Stevens-Johnson syndrome, which was reported in a patient while receiving adjunctive lamotrigine during an open-label phase. The patient did not require hospitalisation and recovered uneventfully. Lamotrigine is approved in the US for the maintenance treatment of adults with bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania and mixed episodes) in patients treated for acute mood episodes with standard therapy. The initial recommended monotherapy dosage is 25 mg/day orally which is gradually increased to 200 mg/day over 6 weeks. Dosages over 200 mg/day as monotherapy are not recommended, as no additional efficacy has been demonstrated in clinical trials evaluating dosages up to 400 mg/day. For patients taking valproate semisodium, the initial recommended lamotrigine dosage is 25mg every other day and the target dosage is 100 mg/day from week 6. In recipients of carbamazepine (or other enzyme-inducing drugs), the initial recommended lamotrigine dosage is 50 mg/day, which is gradually increased up to 400 mg/day from week 7. Dosages ≥50 mg/day can be given once-daily or as two divided doses. There are no formal recommendations as to the duration of maintenance therapy in bipolar I disorder. Lamotrigine should be gradually discontinued over a period of at least 2 weeks. The risk of serious rash, including Stevens-Johnson syndrome, may be increased by coadministration of lamotrigine with valproate semisodium, by exceeding the recommended initial lamotrigine dosage or by exceeding the recommended dosage titration. Lamotrigine should be discontinued at the first sign of any rash, unless the rash is clearly not drug-related. Reduced maintenance dosages are recommended for patients with hepatic impairment.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (19) , 2029-2050
Lamotrigine
Lamotrigine (Lamictal®), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder. The mechanism of action of the drug in patients with bipolar disorder may be related to the inhibition of sodium and calcium channels in presynaptic neurons and subsequent stabilisation of the neuronal membrane. Lamotrigine monotherapy significantly delayed time to intervention with additional pharmacotherapy or electroconvulsive therapy for any new mood episode (mania, hypomania, depression and mixed episodes), compared with placebo, in two large, randomised, double-blind trials of 18 months’ duration. Additionally, lamotrigine was significantly superior to placebo at prolonging time to intervention for depression. These effects of lamotrigine were demonstrated in both recently manic/hypomanic and recently depressed patients. Lamotrigine showed efficacy in delaying manic/hypomanic episodes in pooled data only, although lithium was superior to lamotrigine on this measure. Two of four double-blind, short-term studies have shown lamotrigine to be more effective than placebo in the treatment of patients with treatment-refractory bipolar disorder or those with bipolar depression. Lamotrigine has not demonstrated efficacy in the treatment of acute mania. Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia. Incidences of diarrhoea and tremor were significantly lower in lamotrigine-than in lithium-treated patients. The incidence of serious rash with lamotrigine treatment was 0.1% in all studies of bipolar disorder and included one case of mild Stevens-Johnson syndrome. Lamotrigine did not appear to cause bodyweight gain. The dosage of lamotrigine is titrated over a 6-week period to 200 mg/day to minimise the incidence of serious rash. Adjustments to the initial and target dosages are required if coadministered with valproate semisodium or carbamazepine. Conclusion: Lamotrigine has been shown to be an effective maintenance therapy for patients with bipolar I disorder, significantly delaying time to intervention for any mood episode. Additionally, lamotrigine significantly delayed time to intervention for a depressive episode and showed limited efficacy in delaying time to intervention for a manic/hypomanic episode, compared with placebo. Although not approved for the short-term treatment of mood episodes, lamotrigine has shown efficacy in the acute treatment of patients with bipolar depression but has not demonstrated efficacy in the treatment of acute mania. Lamotrigine is generally well tolerated, does not appear to cause bodyweight gain and, unlike lithium, generally does not require monitoring of serum levels. Lamotrigine is a phenyltriazine derivative. The mechanism of action of the drug in the treatment of patients with bipolar disorder is not fully understood, but may be related to the inhibition of sodium and calcium channels in presynaptic neurons and subsequent stabilisation of the neuronal membrane. In addition, lamotrigine has demonstrated neuroprotective effects in animal models. Lamotrigine lacks appreciable in vitro affinity for dopaminergic, adrenergic, muscarinic, opioid and adenosine receptors at clinically relevant concentrations, but binds weakly to serotonin 5HT3 receptors. It also down-regulates cortical 5HT1A receptor-mediated adenyl cyclase responses in an animal model. Normal synaptic conduction is unaffected by lamotrigine, which suppresses abnormal (sustained repetitive) firing of sodium-dependent action potentials in animal models. Early studies in patients with epilepsy who received lamotrigine indicated a propensity for improved mood, which led to controlled clinical trials in patients with bipolar disorder. Lamotrigine has minimal effects on psychomotor, cognitive and memory function and appears not to be associated with sedative effects or bodyweight gain. Oral lamotrigine is readily bioavailable (98%), and undergoes minimal first-pass metabolism. Absorption of lamotrigine is unaffected by food. Linear pharmacokinetics show peak lamotrigine concentrations occurring 1–3 hours after a dose. Mean protein binding is 55–68% and the drug is widely distributed to all organs and tissues, including brain tissue. It also crosses the placenta and is found in the fetus and in breast milk. Lamotrigine is extensively metabolised in the liver, predominantly via N-glucuronidation (the rate-limiting step in elimination of the drug). Clearance is 1.6–2.6 L/h and the mean plasma elimination half-life is 25–35 hours. Lamotrigine pharmacokinetics appear not to be significantly altered by many commonly used psychotropic agents, nor does lamotrigine alter the pharmacokinetics of lithium. However, enzyme-inhibiting drugs (e.g. valproate semi-sodium) increase lamotrigine plasma concentrations and enzyme-inducing drugs (e.g. carbamazepine) decrease lamotrigine concentrations. Lamotrigine appears not to have clinically significant reciprocal effects on the pharmacokinetics of these drugs. Lamotrigine has been shown to be an effective maintenance treatment in patients with bipolar I disorder who have had a recent depressive or manic/hypomanic episode. Data from two placebo-controlled, double-blind, 18-month comparative studies showed that lamotrigine (100–400 mg/day) or lithium (dose titrated to a serum level of 0.8–1.1 mEq/L) each significantly delayed the time to intervention with additional pharmacotherapy or electroconvulsive therapy for an emerging mood episode compared with placebo (p < 0.05 for lamotrigine vs placebo and for lithium vs placebo in both studies). In addition, both studies showed that lamotrigine, but not lithium, was significantly superior to placebo at prolonging time to intervention for a depressive mood episode. Similarly lithium, but not lamotrigine, was significantly better than placebo at delaying time to intervention for an emerging manic/hypomanic episode. However, in pooled data lamotrigine also significantly delayed time to intervention for a manic/hypomanic episode, although lithium was superior to lamotrigine on this measure. Lamotrigine was shown to be more effective than placebo in the treatment of patients with treatment-refractory bipolar disorder or those with bipolar depression in two of four double-blind short-term studies. Lamotrigine has not demonstrated efficacy in the treatment of acute mania. Lamotrigine 100–400 mg/day as monotherapy was generally well tolerated in two maintenance trials in patients with bipolar I disorder, with a similar adverse event profile to that of placebo. The most common adverse events were headache (19%), nausea (14%), infection (13%) and insomnia (10%). Significantly fewer lamotrigine recipients, compared with those receiving lithium, reported diarrhoea and tremor. The incidence of adverse events was similar in patients who received lamotrigine dosages of 50 mg/day compared with those who received 200 mg/day. Maintenance therapy with lamotrigine did not appear to increase bodyweight after 52 weeks’ treatment. Obese patients (body mass index ≥30 kg/m2) receiving lamotrigine lost an average 2.96kg, whereas those who received lithium or placebo gained 3.3 and 1.46kg, respectively. In a meta-analysis of eight randomised, double-blind, placebo-controlled trials in patients with bipolar disorder, serious adverse events occurred at a similar rate in patients receiving lamotrigine (8%), lithium (8%) and placebo (7%). Induction of mania was the most common serious adverse event and occurred in 3% of patients in each treatment group. The incidence of suicide per year in the meta-analysis was similar between patients receiving lamotrigine and placebo (0.7% vs 0.6%) while no suicides occurred among lithium recipients. Suicide attempts occurred at a similar rate per year in both lamotrigine (1.8%) and placebo (1.1%) recipients. Sexual problems were reported in <1% of patients receiving lamotrigine. Three of 2272 (0.1%) patients receiving lamotrigine in all controlled and uncontrolled bipolar disorder studies developed a serious rash, including one case of mild Stevens-Johnson syndrome, which was reported in a patient while receiving adjunctive lamotrigine during an open-label phase. The patient did not require hospitalisation and recovered uneventfully. Lamotrigine is approved in the US for the maintenance treatment of adults with bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania and mixed episodes) in patients treated for acute mood episodes with standard therapy. The initial recommended monotherapy dosage is 25 mg/day orally which is gradually increased to 200 mg/day over 6 weeks. Dosages over 200 mg/day as monotherapy are not recommended, as no additional efficacy has been demonstrated in clinical trials evaluating dosages up to 400 mg/day. For patients taking valproate semisodium, the initial recommended lamotrigine dosage is 25mg every other day and the target dosage is 100 mg/day from week 6. In recipients of carbamazepine (or other enzyme-inducing drugs), the initial recommended lamotrigine dosage is 50 mg/day, which is gradually increased up to 400 mg/day from week 7. Dosages ≥50 mg/day can be given once-daily or as two divided doses. There are no formal recommendations as to the duration of maintenance therapy in bipolar I disorder. Lamotrigine should be gradually discontinued over a period of at least 2 weeks. The risk of serious rash, including Stevens-Johnson syndrome, may be increased by coadministration of lamotrigine with valproate semisodium, by exceeding the recommended initial lamotrigine dosage or by exceeding the recommended dosage titration. Lamotrigine should be discontinued at the first sign of any rash, unless the rash is clearly not drug-related. Reduced maintenance dosages are recommended for patients with hepatic impairment.
- 1 January 2003
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (12) , 885-912
Eptifibatide
Eptifibatide (Integrilin®) is a selective inhibitor of platelet glycoprotein (GP) IIb/ IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI. Most economic analyses of eptifibatide have incorporated clinical and healthcare resource use data from either the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin® Therapy) study in low-to moderate-risk patients undergoing selective PCI with stent implantation or the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin® Therapy) trial in patients with ACS. Eptifibatide achieved statistically significant reductions in combined endpoints of death and ischaemic complications in both of these large multicentre clinical trials, in which patients were randomised to receive intravenous eptifibatide or placebo as adjunctive therapy to heparin and aspirin (plus a thienopyridine in ESPRIT). In US economic analyses using ESPRIT trial data, approximately 40% and 70% of the acquisition cost of eptifibatide was offset by reduced medical resource consumption during the initial hospitalisation period and over a 1-year period, respectively. Eptifibatide was associated with a favourable cost-effectiveness ratio of $US1407 (year 2000 costs) per life-year gained (LYG) in a retrospective US cost-effectiveness analysis that incorporated data from the ESPRIT trial and modelled life expectancy using a large cardiovascular database. Several cost-effectiveness analyses used prospectively collected data from the PURSUIT trial and modelled survival projections using similar methods. These analyses, conducted in the US, Canada and Western Europe, also showed favourable results ($US3761–$US18 774 per LYG; various years of costing). Cost-utility ratios reported in US analyses varied somewhat, but remained <$US20 000 per quality-adjusted life-year gained (1996 values) when clinical efficacy data were derived from the US cohort of PURSUIT. Conclusion: Significant clinical benefits have been demonstrated with eptifibatide as adjunctive therapy in patients undergoing selective PCI with stent implantation in the ESPRIT trial and in patients with ACS in the PURSUIT trial. Pharmacoeconomic analyses using data from either ESPRIT or PURSUIT have demonstrated favourable cost-effectiveness ratios for both indications in various countries. ESPRIT-based results from the limited number of available economic analyses are particularly favourable. The cost-effectiveness of eptifibatide in ACS (i.e. PURSUIT-based results) may be further improved by targeting the drug for patients in whom catheterisation and PCI are planned, although further analyses are required to confirm this. Percutaneous coronary intervention (PCI) refers to all forms of percutaneous mechanical revascularisation and is a relatively common intervention in patients with coronary artery disease, with more than 1 million angioplasty procedures conducted in the US each year. Acute coronary syndromes (ACS), for the purposes of this review, comprise unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI). Each year, approximately 2–2.5 million patients are hospitalised worldwide because of unstable angina or NSTEMI, and at least half of these are in the US. In-hospital costs for patients undergoing PCI and planned stent implantation were estimated at $US10 430 per patient (without a glycoprotein [GP] IIb/IIIa receptor antagonist; year 2000 costs) in a large retrospective US cost analysis, although both higher and lower estimates of costs associated with PCI have also been reported. Total discounted 10-year medical costs were estimated at $US50 254 per patient (1997 values) in a study in 4319 patients with unstable angina who underwent an initial cardiac catheterisation at a US medical centre between 1986 and 1997. More than 40% of costs were incurred during the acute phase of therapy (which did not include GP IIb/IIIa receptor antagonists). GP IIb/IIIa receptor antagonists such as eptifibatide inhibit the final common pathway for platelet aggregation. Therefore, these drugs can play an important role in preventing thrombus formation in coronary arteries, including that caused by mechanical disruption of an atherosclerotic plaque (e.g. during PCI) or via chemically mediated activation of platelet GP IIb/IIIa receptors (e.g. by thromboxane A2 or adenosine diphosphate). Eptifibatide is a selective GP IIb/IIIa receptor antagonist indicated for patients with coronary artery disease who require selective (nonurgent) or urgent PCI and for those with ACS (many of whom require urgent PCI). The drug is administered intravenously and is used as an adjunct to therapy with heparin and aspirin (acetylsalicylic acid). The clinical efficacy of eptifibatide in patients with low- to moderate-risk coronary artery disease undergoing selective PCI with stent implantation was demonstrated in the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin® Therapy) trial. The study excluded higher-risk patients such as those with ongoing chest pain. Patients were randomised to receive eptifibatide (n = 1040) or placebo (n = 1024), in addition to heparin, aspirin and a thienopyridine (clopidogrel or ticlopidine). Eptifibatide was administered as a bolus of 180 μg/kg followed immediately by a continuous infusion of 2 μg/kg/min (for 18–24 hours or until discharge from hospital, whichever occurred first), and a second bolus dose of 180 ug/kg administered 10 minutes after the first bolus. Results of the primary efficacy analysis showed that, at 48 hours after randomisation, 6.6% of eptifibatide recipients and 10.5% of placebo recipients (p = 0.0015) had either died, experienced a myocardial infarction, underwent urgent target vessel revascularisation (UTVR), or required open-label eptifibatide because of thrombotic complications. An important secondary combined endpoint of death, myocardial infarction and UTVR at 30 days was similarly reduced with eptifibatide versus placebo (6.8% vs 10.5%, p = 0.0034). The clinical efficacy of eptifibatide in patients with ACS was demonstrated in the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin® Therapy) trial. In this large, double-blind, multicentre study, analysis of efficacy included 9461 patients who were randomised to receive eptifibatide (180 μg/kg bolus followed by a continuous infusion of 2 μg/kg/min until hospital discharge for up to a duration of 72 hours, or up to 96 hours in those who underwent PCI) or placebo. A large majority of patients received concomitant heparin and aspirin, although such therapy was not mandated in this trial. For the primary endpoint of death or myocardial infarction at 30 days after randomisation, eptifibatide was associated with a significant benefit compared with placebo (14.2% vs 15.7% of patients, p = 0.04), and this effect was observed early during therapy. Approximately 13% of patients required early PCI within 72 hours of randomisation, and eptifibatide appeared to be particularly beneficial for this subgroup. However, results of subgroup analyses with inadequate statistical power must be interpreted with caution. The most important adverse events associated with eptifibatide are major and minor bleeding (including the need for transfusion). In general, the incidence of bleeding and the need for transfusion was greater with eptifibatide than placebo in large multicentre trials. However, the incidence of bleeding complications varied widely between the studies, possibly because of differences in risk factors and eptifibatide dosage protocols. Stroke was reported in 0.7% of eptifibatide recipients and a similar proportion of placebo recipients (0.8%) in the PURSUIT study. Stroke was rare in the ESPRIT trial and haemorrhagic stroke was rare in both multicentre studies. In Patients Undergoing PCI: Prospective economic analyses of the ESPRIT trial in patients undergoing selective PCI with stent implantation have not been conducted. However, a detailed retrospective cost analysis and a briefly reported cost-effectiveness analysis have been conducted in the US using actual medical resource consumption from the ESPRIT study where possible. Results of the US cost analysis showed that total medical costs associated with the initial hospitalisation were 2.8% higher among eptifibatide than placebo recipients ($US10 722 vs $US10 430 per patient; p < 0.001) [year 2000 costs]. Approximately 40% of the $US495 per patient acquisition cost of eptifibatide was offset by reduced medical resource consumption during the index hospitalisation. The US cost-effectiveness analysis, which examined the incremental costs and benefits of eptifibatide as an adjunct to standard therapy versus standard therapy alone, used 1-year follow-up data from the ESPRIT study and modelled life expectancy using the Duke Cardiovascular Database. In addition to basic life-expectancy projections, the effect of a nonfatal myocardial infarction on subsequent survival was also incorporated into the model. Results showed that the mean incremental cost of eptifibatide was $US146 per patient ($US12 844 vs $US12 697; year 2000 costs) and life expectancy (discounted at 3%) was projected to increase by 0.104 years, thus providing a favourable cost-effectiveness ratio of $US1407 per life-year gained (LYG). (Minor calculation discrepancies are presumably due to rounding.) Approximately 70% of the acquisition cost of eptifibatide was therefore offset by reduced medical resource consumption during the first year. Cost-effectiveness ratios remained below $US2275 per LYG in the sensitivity analysis, even when the prognostic significance of a nonfatal myocardial infarction was eliminated. In addition, a Canadian cost-effectiveness analysis using data from ESPRIT and a hospital cost database reported that eptifibatide was dominant over standard therapy (i.e. less costly and more effective); however, further details are lacking in this brief report. A number of retrospective and prospective economic analyses have been conducted comparing eptifibatide with abciximab as adjunctive therapy in patients undergoing PCI. Study methodology was not uniform across these analyses, all of which were conducted in the US. In general, results showed that eptifibatide was associated with lower acquisition costs and similar or lower total medical costs or charges per patient, while clinical outcomes appeared to be similar between the two GP IIb/IIIa receptor antagonists. Two prospectively conducted comparisons have been performed. In a randomised trial in 320 patients undergoing selective PCI, total inpatient costs were the primary endpoint. Median total in-hospital costs per patient (1999/2000 values) were $US7207 with eptifibatide compared with $US8268 for abciximab (p < 0.01), and clinical efficacy was deemed to be similar between treatment groups. The difference in total medical costs was primarily because of the lower acquisition cost for eptifibatide versus abciximab. The other prospective study was not randomised and did not include a formal economic analysis per se. Nevertheless, the acquisition cost of eptifibatide was lower than that of abciximab and there was little difference between groups in terms of major cost drivers (e.g. length of hospital stay, major adverse cardiovascular events) when used in patients undergoing PCI for a variety of indications. Analyses in Patients with ACS: A number of pharmacoeconomic analyses of eptifibatide in ACS (with or without PCI) have been conducted prospectively using data from the PURSUIT trial. In these analyses, medical resource consumption data were collected for the US, Canadian, Western European and other specific cohorts of the PURSUIT trial, and unit costs for the geographical region of interest were then applied to determine total medical costs per patient. In all of these studies, the acquisition cost of eptifibatide was at least partly offset by a reduced need for medical intervention. Total medical costs, measured over a 6-month period in the majority of analyses, were 1.1–6.8% higher among eptifibatide than placebo recipients, although UK-specific resource consumption was lower in the eptifibatide group. Several of the studies were cost-effectiveness analyses, in which long-term survival was estimated using modelled projections made from 6-month results of the PURSUIT trial, in most cases for the cohort of patients from the particular geographical region of the economic substudy. Cost-effectiveness ratios, which reflected incremental costs and benefits of eptifibatide as an adjunct to standard therapy versus standard therapy alone, were favourable for eptifibatide and ranged from approximately $US3761–$US18 774 per LYG (various years of costing). Values not reported in US dollars were converted using mid-year exchange rates for the year of costing or, if not provided, for the year of study publication. One US analysis also reported a cost-utility ratio of $US19 693 per quality-adjusted life-year (QALY) gained (1996 costs), although a somewhat less favourable cost-utility ratio ($US42 469 per QALY; year of costing not provided) was reported by other US investigators who used clinical results of the entire study population of PURSUIT (rather than the more favourable results of the US cohort) to estimate long-term survival.
- 1 January 2003
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (12) , 885-912
Eptifibatide
Eptifibatide (Integrilin®) is a selective inhibitor of platelet glycoprotein (GP) IIb/ IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI. Most economic analyses of eptifibatide have incorporated clinical and healthcare resource use data from either the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin® Therapy) study in low-to moderate-risk patients undergoing selective PCI with stent implantation or the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin® Therapy) trial in patients with ACS. Eptifibatide achieved statistically significant reductions in combined endpoints of death and ischaemic complications in both of these large multicentre clinical trials, in which patients were randomised to receive intravenous eptifibatide or placebo as adjunctive therapy to heparin and aspirin (plus a thienopyridine in ESPRIT). In US economic analyses using ESPRIT trial data, approximately 40% and 70% of the acquisition cost of eptifibatide was offset by reduced medical resource consumption during the initial hospitalisation period and over a 1-year period, respectively. Eptifibatide was associated with a favourable cost-effectiveness ratio of $US1407 (year 2000 costs) per life-year gained (LYG) in a retrospective US cost-effectiveness analysis that incorporated data from the ESPRIT trial and modelled life expectancy using a large cardiovascular database. Several cost-effectiveness analyses used prospectively collected data from the PURSUIT trial and modelled survival projections using similar methods. These analyses, conducted in the US, Canada and Western Europe, also showed favourable results ($US3761–$US18 774 per LYG; various years of costing). Cost-utility ratios reported in US analyses varied somewhat, but remained <$US20 000 per quality-adjusted life-year gained (1996 values) when clinical efficacy data were derived from the US cohort of PURSUIT. Conclusion: Significant clinical benefits have been demonstrated with eptifibatide as adjunctive therapy in patients undergoing selective PCI with stent implantation in the ESPRIT trial and in patients with ACS in the PURSUIT trial. Pharmacoeconomic analyses using data from either ESPRIT or PURSUIT have demonstrated favourable cost-effectiveness ratios for both indications in various countries. ESPRIT-based results from the limited number of available economic analyses are particularly favourable. The cost-effectiveness of eptifibatide in ACS (i.e. PURSUIT-based results) may be further improved by targeting the drug for patients in whom catheterisation and PCI are planned, although further analyses are required to confirm this. Percutaneous coronary intervention (PCI) refers to all forms of percutaneous mechanical revascularisation and is a relatively common intervention in patients with coronary artery disease, with more than 1 million angioplasty procedures conducted in the US each year. Acute coronary syndromes (ACS), for the purposes of this review, comprise unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI). Each year, approximately 2–2.5 million patients are hospitalised worldwide because of unstable angina or NSTEMI, and at least half of these are in the US. In-hospital costs for patients undergoing PCI and planned stent implantation were estimated at $US10 430 per patient (without a glycoprotein [GP] IIb/IIIa receptor antagonist; year 2000 costs) in a large retrospective US cost analysis, although both higher and lower estimates of costs associated with PCI have also been reported. Total discounted 10-year medical costs were estimated at $US50 254 per patient (1997 values) in a study in 4319 patients with unstable angina who underwent an initial cardiac catheterisation at a US medical centre between 1986 and 1997. More than 40% of costs were incurred during the acute phase of therapy (which did not include GP IIb/IIIa receptor antagonists). GP IIb/IIIa receptor antagonists such as eptifibatide inhibit the final common pathway for platelet aggregation. Therefore, these drugs can play an important role in preventing thrombus formation in coronary arteries, including that caused by mechanical disruption of an atherosclerotic plaque (e.g. during PCI) or via chemically mediated activation of platelet GP IIb/IIIa receptors (e.g. by thromboxane A2 or adenosine diphosphate). Eptifibatide is a selective GP IIb/IIIa receptor antagonist indicated for patients with coronary artery disease who require selective (nonurgent) or urgent PCI and for those with ACS (many of whom require urgent PCI). The drug is administered intravenously and is used as an adjunct to therapy with heparin and aspirin (acetylsalicylic acid). The clinical efficacy of eptifibatide in patients with low- to moderate-risk coronary artery disease undergoing selective PCI with stent implantation was demonstrated in the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin® Therapy) trial. The study excluded higher-risk patients such as those with ongoing chest pain. Patients were randomised to receive eptifibatide (n = 1040) or placebo (n = 1024), in addition to heparin, aspirin and a thienopyridine (clopidogrel or ticlopidine). Eptifibatide was administered as a bolus of 180 μg/kg followed immediately by a continuous infusion of 2 μg/kg/min (for 18–24 hours or until discharge from hospital, whichever occurred first), and a second bolus dose of 180 ug/kg administered 10 minutes after the first bolus. Results of the primary efficacy analysis showed that, at 48 hours after randomisation, 6.6% of eptifibatide recipients and 10.5% of placebo recipients (p = 0.0015) had either died, experienced a myocardial infarction, underwent urgent target vessel revascularisation (UTVR), or required open-label eptifibatide because of thrombotic complications. An important secondary combined endpoint of death, myocardial infarction and UTVR at 30 days was similarly reduced with eptifibatide versus placebo (6.8% vs 10.5%, p = 0.0034). The clinical efficacy of eptifibatide in patients with ACS was demonstrated in the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin® Therapy) trial. In this large, double-blind, multicentre study, analysis of efficacy included 9461 patients who were randomised to receive eptifibatide (180 μg/kg bolus followed by a continuous infusion of 2 μg/kg/min until hospital discharge for up to a duration of 72 hours, or up to 96 hours in those who underwent PCI) or placebo. A large majority of patients received concomitant heparin and aspirin, although such therapy was not mandated in this trial. For the primary endpoint of death or myocardial infarction at 30 days after randomisation, eptifibatide was associated with a significant benefit compared with placebo (14.2% vs 15.7% of patients, p = 0.04), and this effect was observed early during therapy. Approximately 13% of patients required early PCI within 72 hours of randomisation, and eptifibatide appeared to be particularly beneficial for this subgroup. However, results of subgroup analyses with inadequate statistical power must be interpreted with caution. The most important adverse events associated with eptifibatide are major and minor bleeding (including the need for transfusion). In general, the incidence of bleeding and the need for transfusion was greater with eptifibatide than placebo in large multicentre trials. However, the incidence of bleeding complications varied widely between the studies, possibly because of differences in risk factors and eptifibatide dosage protocols. Stroke was reported in 0.7% of eptifibatide recipients and a similar proportion of placebo recipients (0.8%) in the PURSUIT study. Stroke was rare in the ESPRIT trial and haemorrhagic stroke was rare in both multicentre studies. In Patients Undergoing PCI: Prospective economic analyses of the ESPRIT trial in patients undergoing selective PCI with stent implantation have not been conducted. However, a detailed retrospective cost analysis and a briefly reported cost-effectiveness analysis have been conducted in the US using actual medical resource consumption from the ESPRIT study where possible. Results of the US cost analysis showed that total medical costs associated with the initial hospitalisation were 2.8% higher among eptifibatide than placebo recipients ($US10 722 vs $US10 430 per patient; p < 0.001) [year 2000 costs]. Approximately 40% of the $US495 per patient acquisition cost of eptifibatide was offset by reduced medical resource consumption during the index hospitalisation. The US cost-effectiveness analysis, which examined the incremental costs and benefits of eptifibatide as an adjunct to standard therapy versus standard therapy alone, used 1-year follow-up data from the ESPRIT study and modelled life expectancy using the Duke Cardiovascular Database. In addition to basic life-expectancy projections, the effect of a nonfatal myocardial infarction on subsequent survival was also incorporated into the model. Results showed that the mean incremental cost of eptifibatide was $US146 per patient ($US12 844 vs $US12 697; year 2000 costs) and life expectancy (discounted at 3%) was projected to increase by 0.104 years, thus providing a favourable cost-effectiveness ratio of $US1407 per life-year gained (LYG). (Minor calculation discrepancies are presumably due to rounding.) Approximately 70% of the acquisition cost of eptifibatide was therefore offset by reduced medical resource consumption during the first year. Cost-effectiveness ratios remained below $US2275 per LYG in the sensitivity analysis, even when the prognostic significance of a nonfatal myocardial infarction was eliminated. In addition, a Canadian cost-effectiveness analysis using data from ESPRIT and a hospital cost database reported that eptifibatide was dominant over standard therapy (i.e. less costly and more effective); however, further details are lacking in this brief report. A number of retrospective and prospective economic analyses have been conducted comparing eptifibatide with abciximab as adjunctive therapy in patients undergoing PCI. Study methodology was not uniform across these analyses, all of which were conducted in the US. In general, results showed that eptifibatide was associated with lower acquisition costs and similar or lower total medical costs or charges per patient, while clinical outcomes appeared to be similar between the two GP IIb/IIIa receptor antagonists. Two prospectively conducted comparisons have been performed. In a randomised trial in 320 patients undergoing selective PCI, total inpatient costs were the primary endpoint. Median total in-hospital costs per patient (1999/2000 values) were $US7207 with eptifibatide compared with $US8268 for abciximab (p < 0.01), and clinical efficacy was deemed to be similar between treatment groups. The difference in total medical costs was primarily because of the lower acquisition cost for eptifibatide versus abciximab. The other prospective study was not randomised and did not include a formal economic analysis per se. Nevertheless, the acquisition cost of eptifibatide was lower than that of abciximab and there was little difference between groups in terms of major cost drivers (e.g. length of hospital stay, major adverse cardiovascular events) when used in patients undergoing PCI for a variety of indications. Analyses in Patients with ACS: A number of pharmacoeconomic analyses of eptifibatide in ACS (with or without PCI) have been conducted prospectively using data from the PURSUIT trial. In these analyses, medical resource consumption data were collected for the US, Canadian, Western European and other specific cohorts of the PURSUIT trial, and unit costs for the geographical region of interest were then applied to determine total medical costs per patient. In all of these studies, the acquisition cost of eptifibatide was at least partly offset by a reduced need for medical intervention. Total medical costs, measured over a 6-month period in the majority of analyses, were 1.1–6.8% higher among eptifibatide than placebo recipients, although UK-specific resource consumption was lower in the eptifibatide group. Several of the studies were cost-effectiveness analyses, in which long-term survival was estimated using modelled projections made from 6-month results of the PURSUIT trial, in most cases for the cohort of patients from the particular geographical region of the economic substudy. Cost-effectiveness ratios, which reflected incremental costs and benefits of eptifibatide as an adjunct to standard therapy versus standard therapy alone, were favourable for eptifibatide and ranged from approximately $US3761–$US18 774 per LYG (various years of costing). Values not reported in US dollars were converted using mid-year exchange rates for the year of costing or, if not provided, for the year of study publication. One US analysis also reported a cost-utility ratio of $US19 693 per quality-adjusted life-year (QALY) gained (1996 costs), although a somewhat less favourable cost-utility ratio ($US42 469 per QALY; year of costing not provided) was reported by other US investigators who used clinical results of the entire study population of PURSUIT (rather than the more favourable results of the US cohort) to estimate long-term survival.
- 1 January 2003
- Published by Springer Nature in Drugs & Aging
- Vol. 20 (8) , 597-630
Latanoprost
Latanoprost (Xalatan®) is an ester analogue of prostaglandin F2α that reduces intraocular pressure (IOP) by increasing uveoscleral outflow. The IOP-lowering efficacy of latanoprost 0.005% lasts for up to 24 hours after a single topical dose, which allows for a once-daily dosage regimen. In patients with ocular hypertension or open-angle glaucoma, a single drop of latanoprost 0.005% solution (about 1.5 µg) administered topically once daily reduced diurnal IOP by 22 to 39% over 1 to 12 months’ treatment in well-controlled trials; efficacy was maintained during treatment periods of up to 2 years. At this dosage, latanoprost was significantly more effective than timolol 0.5% twice daily in 3 of 4 large, double-blind, randomised studies, was generally as effective as bimatoprost or travoprost, and was significantly more effective than dorzolamide, brimonidine or unoprostone. Furthermore, in patients whose IOP was poorly controlled with timolol, switching to latanoprost monotherapy was at least as effective at lowering IOP as adding dorzolamide or pilocarpine to the regimen. Latanoprost has also shown significant additive effects when used in combination with one or more other glaucoma medications. The fixed combination of latanoprost plus timolol was significantly more effective than either of its individual components in two double-blind randomised studies and more effective than the fixed combination of dorzolamide and timolol in a 3-month, evaluator-masked study. Data in patients with angle-closure glaucoma are limited, but in patients with elevated IOP after undergoing iridotomy, latanoprost 0.005% once daily was significantly more effective than timolol 0.5% twice daily at reducing IOP over 12 weeks of treatment in a large double-blind, randomised study. Latanoprost is generally well tolerated and, unlike timolol, induces minimal systemic adverse events. In well-controlled, 6-month trials, the most commonly occurring drug-related ocular events in latanoprost recipients were mild to moderate conjunctival hyperaemia (3 to 15%) and iris colour change (2 to 9%); these seldom required patient withdrawal although the latter may be permanent. Latanoprost 0.005% as a single daily drop has shown good IOP-lowering efficacy in patients with open-angle glaucoma or ocular hypertension and does not produce the cardiopulmonary adverse effects associated with β-blockers. Thus, latanoprost is a valuable addition to the first-line treatment options for patients with open-angle glaucoma or ocular hypertension. In addition, adjunctive treatment with latanoprost in patients who are refractory to β-blocker therapy is a viable, second-line treatment option. Although preliminary findings are promising, wider clinical experience is required to define the place of latanoprost in the treatment of angle-closure glaucoma. Latanoprost is an ester prodrug analogue of prostaglandin F2α with a high selectivity for the FP subtype of prostanoid receptors. Like other topically applied prostaglandins, latanoprost reduces intraocular pressure (IOP) by increasing uveoscleral outflow facility. IOP reductions were maximal within 8 to 12 hours after a single topical dose of latanoprost (0.005%), and IOP remained below pretreatment levels for at least 24 hours. In addition, latanoprost showed little or no effect on aqueous humour flow, tonographic or fluorophotometric outflow facility, and did not disrupt the blood-aqueous barrier over short-term or long-term treatment. It is thought that the iridial darkening induced by latanoprost is due to enhanced melanin production. Latanoprost 0.005% once daily either increased or had no appreciable effect on ocular circulation in patients with ocular hypertension or open-angle glaucoma. In one investigation, latanoprost increased diurnal ocular perfusion pressure to a significantly greater extent than timolol in patients with normal-tension glaucoma. Results from one study investigating the effects of latanoprost in in vitro and/or in vivo models of retinal injury suggest that this agent may have neuroprotective effects. In patients undergoing cataract surgery the mean maximum concentration (Cmax) of latanoprost in the aqueous humour was 32.6 µg/L, the elimination half life (t½) was 2.5 hours and the concentration 24 hours after administration was ≤0.2 µg/L. Following topical administration of latanoprost (30µL of a 50 µg/mL solution), t½ was 17 minutes, the area under the latanoprost plasma concentration time curve was 34 ng·h/L, and volume of distribution was 0.36 L/kg. Plasma Cmax after topical application of latanoprost was 53 ng/L after 5 minutes. In healthy volunteers, 87.9% of a radiolabelled latanoprost dose was recovered in the urine and 15.3% in the faeces after topical administration. The IOP-lowering efficacy of latanoprost ophthalmic solution (0.005%; 50 µg/mL) has been evaluated in patients with ocular hypertension or open-angle glaucoma, angle-closure glaucoma and other types of glaucoma. Latanoprost was administered as a single drop (about 1.5µg) once daily in all studies (unless otherwise indicated). Open-Angle Glaucoma or Ocular Hypertension: In well-controlled clinical trials including patients with open-angle glaucoma or ocular hypertension (IOP ≥21mm Hg), monotherapy with latanoprost reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment. Latanoprost was significantly more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. In these studies, mean baseline diurnal IOP was reduced by 6.2 to 8.6mm Hg (27 to 35%) with latanoprost and 4.4 to 8.3mm Hg (19 to 33%) with timolol over 3 or 6 months of treatment. Latanoprost demonstrated a stable long-term IOP-lowering effect in 1- or 2-year continuations of these trials, with no sign of diminishing effect during prolonged treatment. In other randomised studies, latanoprost was generally as effective as bimatoprost (0.3% once daily) or travoprost (0.0015 or 0.004% once daily), and was significantly more effective than dorzolamide (2% three times daily), brimonidine (0.2% twice daily), or unoprostone (0.12 or 0.15% twice daily) at reducing IOP over 1 to 12 months’ treatment. In patients who had elevated IOP despite timolol treatment, switching to latanoprost monotherapy was at least as effective at reducing diurnal IOP as adding dorzolamide (2% twice daily) or pilocarpine (2% three times daily) to the regimen: mean diurnal IOP was reduced by 19 to 26%, 17 to 21% and 19 to 20%, respectively, over 6 weeks’ to 6 months’ treatment in randomised studies (n = 35 to 197). The fixed combination of latanoprost plus timolol was significantly more effective than either of its individual components in two 6-month double-blind randomised studies and was also more effective than the fixed combination of dorzolamide plus timolol in a 3-month, evaluator masked study. When added to existing therapy with a β-blocker (usually timolol), latanoprost was significantly more effective than pilocarpine (2% three times daily) and dorzolamide (2% twice daily), and as effective as brimonidine (0.2% twice daily) at reducing IOP in randomised studies. Mean IOP was reduced by 24 to 32% with adjunctive latanoprost, 19 to 21% with adjunctive pilocarpine, 20% with adjunctive dorzolamide and 22% with adjunctive brimonidine. Latanoprost also demonstrated additive effects when used in combination with a variety of other IOP-lowering medications including dipivefrine, acetazolamide, dorzolamide and pilocarpine (but not unoprostone) in other studies. In patients who had persistently elevated IOP despite receiving two or more IOP-lowering medications, latanoprost reduced IOP by a further 16 to 18% in noncomparative trials. In the only randomised study, latanoprost showed similar IOP-lowering efficacy to brimonidine 0.2% twice daily when these drugs were added to therapy with a β-blocker combined with pilocarpine or dorzolamide. Angle-Closure Glaucoma: In patients who had elevated IOP despite iridotomy and/or iridectomy (including patients of Asian decent), latanoprost (0.005% once daily) was significantly more effective than timolol (0.5% twice daily) in two double-blind, monotherapy trials (8.2 and 8.8mm Hg vs 5.2 and 5.7mm Hg for latanoprost vs timolol at 12 and 2 weeks, respectively). As adjunctive therapy in a small nonblind trial (patients had undergone iridectomy and were receiving combined treatment with β-blockers and pilocarpine with or without oral carbonic anhydrase inhibitors), latanoprost rapidly decreased mean IOP. Other Types of Glaucoma: In randomised studies in patients with normal-tension glaucoma or steroid-induced glaucoma, latanoprost (0.005% once daily) displayed similar IOP-lowering efficacy to timolol 0.5% twice daily over 3 weeks or 4 months’ treatment, respectively. In patients with pigmentary glaucoma (n = 36), latanoprost produced significantly greater reductions in IOP than timolol after 12 months therapy (5.9 vs 4.6%). Overall, ocular-related adverse effects observed in patients with glaucoma who received latanoprost were mild to moderate in severity and the majority resolved after discontinuation of treatment. Treatment with latanoprost may cause mild conjunctival hyperaemia, iridial darkening and eyelash changes. Increased iridial pigmentation did not resolve upon cessation of latanoprost in patients followed for 2 years. An increase in the severity and recurrence of herpes simplex virus keratitis has been reported after initiation of latanoprost therapy and caution is advised in patients with a history of herpes. Anecdotal evidence has suggested development of cystoid macular oedema as a potentially serious adverse effect associated with latanoprost treatment in patients with independent risk factors. Anterior uveitis has also been observed in approximately 1% of patients receiving latanoprost and is resolved with corticosteroid therapy. Administration of latanoprost to patients with active uveitis at the time of treatment may or may not aggravate the condition, but does not appear to lower IOP. Latanoprost-related systemic adverse events are infrequent (unlike those induced by timolol) but include respiratory complications and headache. A similar incidence of adverse effects has been observed in short-term (range 30 days to 8 weeks) randomised studies of latanoprost with the prostaglandins bimatoprost or unoprostone, although in one study unoprostone recipients experienced more frequent adverse events than latanoprost recipients. Significantly more conjunctive hyperaemia and increased eyelash growth was reported in patients who received bimatoprost than latanoprost for 3 months and headache was more frequently seen in latanoprost than bimatoprost patients. Latanoprost has also shown a similar incidence of adverse effects to both dorzolamide and brimonidine; systemic effects are more pronounced with dorzolamide. In the US, Europe and Japan latanoprost is approved for first-line use in patients with open-angle glaucoma or ocular hypertension. A single drop of latanoprost 0.005% ophthalmic solution (about 1.5µg) once daily is the recommended dosage. The drug should be used cautiously in patients with renal or hepatic impairment and in patients with active intraocular inflammation (e.g. iritis, uveitis). Contact lenses should be removed before administration of latanoprost.
- 1 January 2003
- Published by Springer Nature in Drugs & Aging
- Vol. 20 (8) , 597-630
Latanoprost
Latanoprost (Xalatan®) is an ester analogue of prostaglandin F2α that reduces intraocular pressure (IOP) by increasing uveoscleral outflow. The IOP-lowering efficacy of latanoprost 0.005% lasts for up to 24 hours after a single topical dose, which allows for a once-daily dosage regimen. In patients with ocular hypertension or open-angle glaucoma, a single drop of latanoprost 0.005% solution (about 1.5 µg) administered topically once daily reduced diurnal IOP by 22 to 39% over 1 to 12 months’ treatment in well-controlled trials; efficacy was maintained during treatment periods of up to 2 years. At this dosage, latanoprost was significantly more effective than timolol 0.5% twice daily in 3 of 4 large, double-blind, randomised studies, was generally as effective as bimatoprost or travoprost, and was significantly more effective than dorzolamide, brimonidine or unoprostone. Furthermore, in patients whose IOP was poorly controlled with timolol, switching to latanoprost monotherapy was at least as effective at lowering IOP as adding dorzolamide or pilocarpine to the regimen. Latanoprost has also shown significant additive effects when used in combination with one or more other glaucoma medications. The fixed combination of latanoprost plus timolol was significantly more effective than either of its individual components in two double-blind randomised studies and more effective than the fixed combination of dorzolamide and timolol in a 3-month, evaluator-masked study. Data in patients with angle-closure glaucoma are limited, but in patients with elevated IOP after undergoing iridotomy, latanoprost 0.005% once daily was significantly more effective than timolol 0.5% twice daily at reducing IOP over 12 weeks of treatment in a large double-blind, randomised study. Latanoprost is generally well tolerated and, unlike timolol, induces minimal systemic adverse events. In well-controlled, 6-month trials, the most commonly occurring drug-related ocular events in latanoprost recipients were mild to moderate conjunctival hyperaemia (3 to 15%) and iris colour change (2 to 9%); these seldom required patient withdrawal although the latter may be permanent. Latanoprost 0.005% as a single daily drop has shown good IOP-lowering efficacy in patients with open-angle glaucoma or ocular hypertension and does not produce the cardiopulmonary adverse effects associated with β-blockers. Thus, latanoprost is a valuable addition to the first-line treatment options for patients with open-angle glaucoma or ocular hypertension. In addition, adjunctive treatment with latanoprost in patients who are refractory to β-blocker therapy is a viable, second-line treatment option. Although preliminary findings are promising, wider clinical experience is required to define the place of latanoprost in the treatment of angle-closure glaucoma. Latanoprost is an ester prodrug analogue of prostaglandin F2α with a high selectivity for the FP subtype of prostanoid receptors. Like other topically applied prostaglandins, latanoprost reduces intraocular pressure (IOP) by increasing uveoscleral outflow facility. IOP reductions were maximal within 8 to 12 hours after a single topical dose of latanoprost (0.005%), and IOP remained below pretreatment levels for at least 24 hours. In addition, latanoprost showed little or no effect on aqueous humour flow, tonographic or fluorophotometric outflow facility, and did not disrupt the blood-aqueous barrier over short-term or long-term treatment. It is thought that the iridial darkening induced by latanoprost is due to enhanced melanin production. Latanoprost 0.005% once daily either increased or had no appreciable effect on ocular circulation in patients with ocular hypertension or open-angle glaucoma. In one investigation, latanoprost increased diurnal ocular perfusion pressure to a significantly greater extent than timolol in patients with normal-tension glaucoma. Results from one study investigating the effects of latanoprost in in vitro and/or in vivo models of retinal injury suggest that this agent may have neuroprotective effects. In patients undergoing cataract surgery the mean maximum concentration (Cmax) of latanoprost in the aqueous humour was 32.6 µg/L, the elimination half life (t½) was 2.5 hours and the concentration 24 hours after administration was ≤0.2 µg/L. Following topical administration of latanoprost (30µL of a 50 µg/mL solution), t½ was 17 minutes, the area under the latanoprost plasma concentration time curve was 34 ng·h/L, and volume of distribution was 0.36 L/kg. Plasma Cmax after topical application of latanoprost was 53 ng/L after 5 minutes. In healthy volunteers, 87.9% of a radiolabelled latanoprost dose was recovered in the urine and 15.3% in the faeces after topical administration. The IOP-lowering efficacy of latanoprost ophthalmic solution (0.005%; 50 µg/mL) has been evaluated in patients with ocular hypertension or open-angle glaucoma, angle-closure glaucoma and other types of glaucoma. Latanoprost was administered as a single drop (about 1.5µg) once daily in all studies (unless otherwise indicated). Open-Angle Glaucoma or Ocular Hypertension: In well-controlled clinical trials including patients with open-angle glaucoma or ocular hypertension (IOP ≥21mm Hg), monotherapy with latanoprost reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment. Latanoprost was significantly more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. In these studies, mean baseline diurnal IOP was reduced by 6.2 to 8.6mm Hg (27 to 35%) with latanoprost and 4.4 to 8.3mm Hg (19 to 33%) with timolol over 3 or 6 months of treatment. Latanoprost demonstrated a stable long-term IOP-lowering effect in 1- or 2-year continuations of these trials, with no sign of diminishing effect during prolonged treatment. In other randomised studies, latanoprost was generally as effective as bimatoprost (0.3% once daily) or travoprost (0.0015 or 0.004% once daily), and was significantly more effective than dorzolamide (2% three times daily), brimonidine (0.2% twice daily), or unoprostone (0.12 or 0.15% twice daily) at reducing IOP over 1 to 12 months’ treatment. In patients who had elevated IOP despite timolol treatment, switching to latanoprost monotherapy was at least as effective at reducing diurnal IOP as adding dorzolamide (2% twice daily) or pilocarpine (2% three times daily) to the regimen: mean diurnal IOP was reduced by 19 to 26%, 17 to 21% and 19 to 20%, respectively, over 6 weeks’ to 6 months’ treatment in randomised studies (n = 35 to 197). The fixed combination of latanoprost plus timolol was significantly more effective than either of its individual components in two 6-month double-blind randomised studies and was also more effective than the fixed combination of dorzolamide plus timolol in a 3-month, evaluator masked study. When added to existing therapy with a β-blocker (usually timolol), latanoprost was significantly more effective than pilocarpine (2% three times daily) and dorzolamide (2% twice daily), and as effective as brimonidine (0.2% twice daily) at reducing IOP in randomised studies. Mean IOP was reduced by 24 to 32% with adjunctive latanoprost, 19 to 21% with adjunctive pilocarpine, 20% with adjunctive dorzolamide and 22% with adjunctive brimonidine. Latanoprost also demonstrated additive effects when used in combination with a variety of other IOP-lowering medications including dipivefrine, acetazolamide, dorzolamide and pilocarpine (but not unoprostone) in other studies. In patients who had persistently elevated IOP despite receiving two or more IOP-lowering medications, latanoprost reduced IOP by a further 16 to 18% in noncomparative trials. In the only randomised study, latanoprost showed similar IOP-lowering efficacy to brimonidine 0.2% twice daily when these drugs were added to therapy with a β-blocker combined with pilocarpine or dorzolamide. Angle-Closure Glaucoma: In patients who had elevated IOP despite iridotomy and/or iridectomy (including patients of Asian decent), latanoprost (0.005% once daily) was significantly more effective than timolol (0.5% twice daily) in two double-blind, monotherapy trials (8.2 and 8.8mm Hg vs 5.2 and 5.7mm Hg for latanoprost vs timolol at 12 and 2 weeks, respectively). As adjunctive therapy in a small nonblind trial (patients had undergone iridectomy and were receiving combined treatment with β-blockers and pilocarpine with or without oral carbonic anhydrase inhibitors), latanoprost rapidly decreased mean IOP. Other Types of Glaucoma: In randomised studies in patients with normal-tension glaucoma or steroid-induced glaucoma, latanoprost (0.005% once daily) displayed similar IOP-lowering efficacy to timolol 0.5% twice daily over 3 weeks or 4 months’ treatment, respectively. In patients with pigmentary glaucoma (n = 36), latanoprost produced significantly greater reductions in IOP than timolol after 12 months therapy (5.9 vs 4.6%). Overall, ocular-related adverse effects observed in patients with glaucoma who received latanoprost were mild to moderate in severity and the majority resolved after discontinuation of treatment. Treatment with latanoprost may cause mild conjunctival hyperaemia, iridial darkening and eyelash changes. Increased iridial pigmentation did not resolve upon cessation of latanoprost in patients followed for 2 years. An increase in the severity and recurrence of herpes simplex virus keratitis has been reported after initiation of latanoprost therapy and caution is advised in patients with a history of herpes. Anecdotal evidence has suggested development of cystoid macular oedema as a potentially serious adverse effect associated with latanoprost treatment in patients with independent risk factors. Anterior uveitis has also been observed in approximately 1% of patients receiving latanoprost and is resolved with corticosteroid therapy. Administration of latanoprost to patients with active uveitis at the time of treatment may or may not aggravate the condition, but does not appear to lower IOP. Latanoprost-related systemic adverse events are infrequent (unlike those induced by timolol) but include respiratory complications and headache. A similar incidence of adverse effects has been observed in short-term (range 30 days to 8 weeks) randomised studies of latanoprost with the prostaglandins bimatoprost or unoprostone, although in one study unoprostone recipients experienced more frequent adverse events than latanoprost recipients. Significantly more conjunctive hyperaemia and increased eyelash growth was reported in patients who received bimatoprost than latanoprost for 3 months and headache was more frequently seen in latanoprost than bimatoprost patients. Latanoprost has also shown a similar incidence of adverse effects to both dorzolamide and brimonidine; systemic effects are more pronounced with dorzolamide. In the US, Europe and Japan latanoprost is approved for first-line use in patients with open-angle glaucoma or ocular hypertension. A single drop of latanoprost 0.005% ophthalmic solution (about 1.5µg) once daily is the recommended dosage. The drug should be used cautiously in patients with renal or hepatic impairment and in patients with active intraocular inflammation (e.g. iritis, uveitis). Contact lenses should be removed before administration of latanoprost.
- 1 January 2002
- Published by Springer Nature in Drugs
- Vol. 62 (15) , 2283-2314
Danaparoid
Danaparoid (danaparoid sodium) is a low molecular weight heparinoid which has undergone clinical study for use as continued anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT), for the prophylaxis and treatment of deep vein thrombosis (DVT), and for the treatment of disseminated intravascular coagulation (DIC). A nonblind study in patients with HIT has reported that complete clinical resolution is significantly more likely in patients receiving danaparoid than in patients receiving dextran 70. In addition, retrospective analyses and non-comparative data support the use of danaparoid for continued anticoagulant therapy in patients with HIT. Studies in patients undergoing hip surgery have shown that danaparoid significantly reduces the incidence of postoperative DVT compared with aspirin, warfarin, dextran 70 and heparin-dihydroergotamine, while additional data suggest no difference between danaparoid, enoxaparin and dalteparin. In patients undergoing abdominal or thoracic surgery for removal of a malignancy, danaparoid reduced the incidence of postoperative DVT compared with placebo, but showed no significant difference when compared with unfractionated heparin (UFH). Two studies have compared danaparoid with UFH in the prophylaxis of DVT following acute ischaemic stroke; twice daily danaparoid was significantly superior to UFH whereas there was no significant difference between a once-daily dosage and UFH. Danaparoid did not differ from UFH in terms of efficacy in the treatment of existing DVT. In all comparative studies examining the efficacy of danaparoid in the prophylaxis or treatment of DVT (versus warfarin, dextran 70, enoxaparin, dalteparin, aspirin, heparin-dihydroergotamine, UFH and placebo), the incidence of haemorrhagic complications did not differ between treatment groups. In patients with DIC, 61.9% of those patients receiving danaparoid experienced either disappearance or reduction of symptoms of DIC whereas 62% of those receiving UFH showed either no change or aggravation of their symptoms. There was no significant difference between treatment groups in tolerability or overall improvement of DIC. Conclusions: Danaparoid is an effective anticoagulant agent which has undergone clinical evaluation in a wide range of disease indications. Current guidelines support the use of danaparoid in prophylaxis of DVT following ischaemic stroke, and in patients who develop HIT. Danaparoid has shown efficacy in DIC, and for DVT prophylaxis in patients undergoing hip surgery although further data are required to establish the role of danaparoid in these indications. In particular, double-blind trials comparing danaparoid with such recommended therapies as the low molecular weight heparins will provide more definitive data on the place of danaparoid in the clinical management of these conditions and ultimately lead to improved patient outcomes. Danaparoid (danaparoid sodium) is a low molecular weight heparinoid, consisting of glycosaminoglycans, with a mean molecular mass of approximately 5500D. Its active components are heparan sulphate (≈84%), dermatan sulphate (≈12%) and chondroitin sulphates A and C (≈4%). Danaparoid catalyses the antithrombin-mediated inactivation of factor Xa leading to an inhibition of thrombin generation and ultimately thrombus formation. Danaparoid also weakly enhances antithrombin III and heparin cofactor II inactivation of factor IIa and has relatively little effect on platelet aggregation. There are no specific assays for determining the plasma concentrations of danaparoid and so pharmacokinetic measurements are based on the kinetics of its anticoagulant activities, primarily plasma antifactor Xa. The majority of data concerning danaparoid anticoagulant activities have been obtained following single-dose injections in healthy volunteers. The absolute bioavailability of danaparoid following subcutaneous injection approaches 100% and peak antifactor Xa activity occurs between 2 and 5 hours after administration. After intravenous administration, danaparoid has a mean distribution half-life of antifactor Xa activity of 2.34 hours. Renal excretion is the main route of elimination, accounting for up to 50% of the total plasma clearance of antifactor Xa activity. No clinically significant drug interactions have been reported between danaparoid and agents which act on platelet function or haemostasis. Oral chlorthalidone significantly increased the volume of distribution (Vd) of antifactor IIa activity, and decreased clearance (CL) and Vd of antifactor Xa activity. Digoxin significantly increased CL of antifactor Xa activity. Treatment of Heparin-induced Thrombocytopenia A small nonblind prospective study has compared danaparoid with dextran 70 as anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT). Patients randomised to danaparoid received a bolus intravenous injection of 2400U, followed by continuous intravenous infusion. Dextran 70 was given as an intravenous infusion of 1L on day 1, followed by infusions of 0.5L daily for the next 4 days. All patients also received concomitant warfarin. Study drugs were started within 24 hours of stopping unfractionated heparin (UFH) and were continued for at least 72 hours. Thrombocytopenia resolved in 23 patients receiving danaparoid (92%) and 15 patients receiving dextran 70 (88%) and the mean time to resolution of HIT did not differ between treatments (6.7 vs 7.3 days). Complete clinical resolution of thromboembolic events and partial or complete clinical recovery was significantly more likely in patients receiving danaparoid than in those receiving dextran 70. A retrospective analysis comparing patients receiving lepirudin as part of a formal clinical trial with patients receiving danaparoid in a general clinical setting has shown no significant difference between the treatments. In 730 patients with HIT receiving danaparoid in three noncomparative studies, thrombocytopenia persisted or appeared de novo in 6.1, 6.5 and 13.6% of patients. Several case reports and a series of 47 patients also document the successful use of danaparoid in the treatment of HIT in pregnant women, paediatric patients and patients undergoing cardiovascular surgery including cardiopulmonary bypass. Prophylaxis and Treatment of Deep Vein Thrombosis Six comparative studies have examined the use of danaparoid for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip surgery (either fracture or hip replacement). Danaparoid was variously administered prior to surgery and then following surgery at a dosage of 750U subcutaneously twice daily. Two large, randomised studies showed that patients receiving danaparoid for 7 to 8 days following surgery developed significantly lower rates of DVT than patients receiving warfarin (patients with hip fracture 7 vs 21%; those with total hip replacement 14.6 vs 26.9%). Similarly, in a double-blind study in patients undergoing surgery for hip fracture, danaparoid was significantly more effective at reducing the incidence of DVT than aspirin (100mg twice daily) after treatment for 14 days following surgery (27.8 vs 44.3%). Randomised comparisons with dextran 70 and with heparin-dihydroergotamine (DHE) also suggest that danaparoid provides effective prophylaxis of DVT. The incidence of DVT in patients receiving danaparoid was significantly lower than in those receiving dextran 70 (10 vs 31%) or heparin-DHE(17 vs 33%). Finally, in a comparison of danaparoid with enoxaparin (40 mg/day subcutaneously) and dalteparin (5000 U/day subcutaneously) in patients undergoing surgery for hip fracture, there was no significant difference in the incidence of DVT between treatment groups (5.7 vs 15.4 vs 8.8%, respectively). Danaparoid has also been compared with UFH for the prophylaxis of DVT in 490 patients undergoing surgery for suspected gastrointestinal malignancy or lung cancer. There was no statistically significant difference in the frequency of positive leg scan results between treatment groups (danaparoid 7.9 vs UFH 11.2%). In two double-blind studies in patients with ischaemic stroke, no significant difference was observed between danaparoid (1250U once daily) and UFH (5000 U/day subcutaneously twice daily) in reducing the incidence of DVT (14.6 vs 19.8%) with treatment for a minimum of 9 days. However, in a separate study, danaparoid (750U twice daily) was significantly more effective than UFH (5000 U/day subcutaneously twice daily) in reducing the occurrence of DVT (9 vs 31%) when treatment was continued for 14 days. In a placebo-controlled, double-blind study, danaparoid (750U twice daily) significantly reduced the incidence of DVT compared with placebo (4 vs 28%). The ‘Trial of ORG 10172 (danaparoid) in Acute Stroke Treatment’ (TOAST) was a multicentre, placebo-controlled study in 1275 patients with acute or progressing ischaemic stroke to assess the effect of danaparoid on neurological outcomes. There was no significant difference in the frequency of favourable outcome (assessed using the Glasgow Outcome Scale and Barthel Index) at 7 days or at 3 months. There was also no significant difference between treatment groups in the frequency of very favourable outcome at 3 months; however, after 7 days’ treatment, significantly more patients receiving danaparoid reported very favourable outcomes compared with those receiving placebo. The incidence of DVT during the 3-month follow-up was significantly lower in patients who received danaparoid than in patients who received placebo. An assessor blind study has compared the efficacy of danaparoid with that of UFH for the treatment of venous thromboembolism in 188 patients. The frequency of recurrence or extension of DVT was significantly lower in patients receiving danaparoid 2000U subcutaneously twice daily (13%) than in those receiving UFH (28%) or in those receiving danaparoid 1250U subcutaneously twice daily (28%) when assessed after 5 to 8 days. Similar results were found 2 months after the initiation of study treatment. Treatment of Disseminated Intravascular Coagulation The use of danaparoid (1250U twice daily) in the treatment of disseminated intravascular coagulation (DIC) was examined in 85 patients in a randomised double-blind, double-dummy comparison with UFH (continuous intravenous infusion of 7 to 10 U/kg/h). There was no significant difference in the rate of change of the underlying condition between treatment groups after 5 days of treatment. Ten patients receiving danaparoid (23.3%) and 12 patients receiving UFH (28.6%) were considered to have an easing or recovery of their underlying condition. Similar numbers of patients in each group showed no change in (55.8 and 47.6%) or aggravation of (20.9 and 23.8%) the severity of their underlying condition. There was also no difference between treatment groups in DIC scores during the study. The only comparative study with danaparoid in the treatment of DIC has reported that 61.9% of patients receiving danaparoid experienced either disappearance or reduction of symptoms of DIC whereas 62% of patients receiving UFH showed either no change or aggravation of their symptoms. Heparin-Induced Thrombocytopenia A noncomparative study has reported that from a total of 667 patients who were receiving danaparoid for antithrombotic medication with associated HIT, 67 developed serious adverse events (including new or extension of thrombosis, skin rash, bleeding, and persistent of recurrent platelet count). Indirect comparison of danaparoid and lepirudin suggests that significantly fewer patients receiving danaparoid developed a major bleeding event than patients receiving lepirudin (2.5 vs 10.4%). Finally, in a prospective nonblind comparative study, one patient receiving danaparoid and three receiving dextran 70 died of HIT-associated thrombosis. Deep Vein Thrombosis In 9 studies which evaluated the efficacy and tolerability of danaparoid in the prophylaxis of DVT following surgery, the incidence of haemorrhagic complications did not differ significantly between danaparoid and the comparator agent. Most studies showed no significant difference between danaparoid and the comparator agent regarding blood loss and transfusion requirements during surgery; however, one study reported that significantly fewer patients receiving danaparoid required a postoperative blood transfusion compared with those receiving dextran 70 and, in a second study, more patients receiving danaparoid required intraoperative blood transfusion compared to those receiving heparin-DHE. Blood loss and mortality were generally similar between treatment groups. In the TOAST study, major bleeding events were significantly more frequent in patients receiving danaparoid during prophylaxis (7 days), within 10 days of starting therapy and throughout the 3-month period of observation than in those receiving placebo (p < 0.05 in all cases). In addition, serious brain bleeding during the initial 10 days of therapy, and minor bleeding during treatment and during the initial 10 days of therapy were also observed significantly more frequently in patients receiving danaparoid than in those receiving placebo (p < 0.05 in each case). Five patients with ischaemic strokes from three studies developed major bleeding complications; three of these patients were receiving danaparoid, one was receiving UFH, and one placebo. One case of a fatal haemorrhagic transformation associated with danaparoid treatment was reported. In patients receiving danaparoid for treatment of DVT, major bleeding occurred in two patients receiving UFH and two receiving danaparoid. Disseminated Intravascular Coagulation Data from the only comparative study with danaparoid in the treatment of DIC suggests that there are no significant tolerability differences between danaparoid and UFH. Three patients receiving UFH and no patients receiving danaparoid experienced bleeding-related adverse events. Throughout Western Europe danaparoid is approved for the treatment of HIT. For continued anticoagulation in patients with HIT, danaparoid should be administered intravenously as abolus of 2500U (1250U if bodyweight is 90kg) followed by a continuous intravenous infusion of 400 U/h for 2 hours, 300 U/h for the next 2 hours, then a maintenance infusion of 200 U/h for 5 days. In the US, danaparoid has received regulatory approval for the prophylaxis of postoperative DVT in patients undergoing elective hip replacement. In Europe, it has received regulatory approval for the prophylaxis of DVT in patients undergoing general or orthopaedic surgery. For DVT prophylaxis, danaparoid should be administered by subcutaneous injection at a dose of 750U twice daily beginning 1 to 4 hours before surgery and then not sooner than 2 hours after surgery. Treatment duration should be 7 to 10 days, and up to 14 days where necessary. In Japan, danaparoid has received regulatory approval for use in the treatment of DIC. The recommended normal adult dosage is 1250U twice daily via intravenous administration. Patients with moderately or severely impaired kidney or liver function, or impaired haemostasis should exercise caution when taking danaparoid, as delayed excretion may lead to haemorrhage. Dosage should be reduced or intervals between dosages increased if serum creatinine levels are ≥2 g/L. In patients with severe renal damage, consideration should be given to suspending treatment. Breast-feeding mothers should only be given danaparoid if clearly required, and the tolerability of danaparoid in infants and paediatric patients has not been confirmed. Finally, danaparoid is contraindicated in patients with haemorrhage (or at risk of haemorrhage), requiring haemodialysis, with severe liver damage, with hypersensitivity to danaparoid, with HIT who display cross-reactivity between danaparoid and HIT antibodies, with diabetic retinopathy and in those who have recently undergone brain, spinal or eye surgery.
- 1 January 2002
- Published by Springer Nature in Drugs
- Vol. 62 (15) , 2283-2314
Danaparoid
Danaparoid (danaparoid sodium) is a low molecular weight heparinoid which has undergone clinical study for use as continued anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT), for the prophylaxis and treatment of deep vein thrombosis (DVT), and for the treatment of disseminated intravascular coagulation (DIC). A nonblind study in patients with HIT has reported that complete clinical resolution is significantly more likely in patients receiving danaparoid than in patients receiving dextran 70. In addition, retrospective analyses and non-comparative data support the use of danaparoid for continued anticoagulant therapy in patients with HIT. Studies in patients undergoing hip surgery have shown that danaparoid significantly reduces the incidence of postoperative DVT compared with aspirin, warfarin, dextran 70 and heparin-dihydroergotamine, while additional data suggest no difference between danaparoid, enoxaparin and dalteparin. In patients undergoing abdominal or thoracic surgery for removal of a malignancy, danaparoid reduced the incidence of postoperative DVT compared with placebo, but showed no significant difference when compared with unfractionated heparin (UFH). Two studies have compared danaparoid with UFH in the prophylaxis of DVT following acute ischaemic stroke; twice daily danaparoid was significantly superior to UFH whereas there was no significant difference between a once-daily dosage and UFH. Danaparoid did not differ from UFH in terms of efficacy in the treatment of existing DVT. In all comparative studies examining the efficacy of danaparoid in the prophylaxis or treatment of DVT (versus warfarin, dextran 70, enoxaparin, dalteparin, aspirin, heparin-dihydroergotamine, UFH and placebo), the incidence of haemorrhagic complications did not differ between treatment groups. In patients with DIC, 61.9% of those patients receiving danaparoid experienced either disappearance or reduction of symptoms of DIC whereas 62% of those receiving UFH showed either no change or aggravation of their symptoms. There was no significant difference between treatment groups in tolerability or overall improvement of DIC. Conclusions: Danaparoid is an effective anticoagulant agent which has undergone clinical evaluation in a wide range of disease indications. Current guidelines support the use of danaparoid in prophylaxis of DVT following ischaemic stroke, and in patients who develop HIT. Danaparoid has shown efficacy in DIC, and for DVT prophylaxis in patients undergoing hip surgery although further data are required to establish the role of danaparoid in these indications. In particular, double-blind trials comparing danaparoid with such recommended therapies as the low molecular weight heparins will provide more definitive data on the place of danaparoid in the clinical management of these conditions and ultimately lead to improved patient outcomes. Danaparoid (danaparoid sodium) is a low molecular weight heparinoid, consisting of glycosaminoglycans, with a mean molecular mass of approximately 5500D. Its active components are heparan sulphate (≈84%), dermatan sulphate (≈12%) and chondroitin sulphates A and C (≈4%). Danaparoid catalyses the antithrombin-mediated inactivation of factor Xa leading to an inhibition of thrombin generation and ultimately thrombus formation. Danaparoid also weakly enhances antithrombin III and heparin cofactor II inactivation of factor IIa and has relatively little effect on platelet aggregation. There are no specific assays for determining the plasma concentrations of danaparoid and so pharmacokinetic measurements are based on the kinetics of its anticoagulant activities, primarily plasma antifactor Xa. The majority of data concerning danaparoid anticoagulant activities have been obtained following single-dose injections in healthy volunteers. The absolute bioavailability of danaparoid following subcutaneous injection approaches 100% and peak antifactor Xa activity occurs between 2 and 5 hours after administration. After intravenous administration, danaparoid has a mean distribution half-life of antifactor Xa activity of 2.34 hours. Renal excretion is the main route of elimination, accounting for up to 50% of the total plasma clearance of antifactor Xa activity. No clinically significant drug interactions have been reported between danaparoid and agents which act on platelet function or haemostasis. Oral chlorthalidone significantly increased the volume of distribution (Vd) of antifactor IIa activity, and decreased clearance (CL) and Vd of antifactor Xa activity. Digoxin significantly increased CL of antifactor Xa activity. Treatment of Heparin-induced Thrombocytopenia A small nonblind prospective study has compared danaparoid with dextran 70 as anticoagulant therapy in patients with heparin-induced thrombocytopenia (HIT). Patients randomised to danaparoid received a bolus intravenous injection of 2400U, followed by continuous intravenous infusion. Dextran 70 was given as an intravenous infusion of 1L on day 1, followed by infusions of 0.5L daily for the next 4 days. All patients also received concomitant warfarin. Study drugs were started within 24 hours of stopping unfractionated heparin (UFH) and were continued for at least 72 hours. Thrombocytopenia resolved in 23 patients receiving danaparoid (92%) and 15 patients receiving dextran 70 (88%) and the mean time to resolution of HIT did not differ between treatments (6.7 vs 7.3 days). Complete clinical resolution of thromboembolic events and partial or complete clinical recovery was significantly more likely in patients receiving danaparoid than in those receiving dextran 70. A retrospective analysis comparing patients receiving lepirudin as part of a formal clinical trial with patients receiving danaparoid in a general clinical setting has shown no significant difference between the treatments. In 730 patients with HIT receiving danaparoid in three noncomparative studies, thrombocytopenia persisted or appeared de novo in 6.1, 6.5 and 13.6% of patients. Several case reports and a series of 47 patients also document the successful use of danaparoid in the treatment of HIT in pregnant women, paediatric patients and patients undergoing cardiovascular surgery including cardiopulmonary bypass. Prophylaxis and Treatment of Deep Vein Thrombosis Six comparative studies have examined the use of danaparoid for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip surgery (either fracture or hip replacement). Danaparoid was variously administered prior to surgery and then following surgery at a dosage of 750U subcutaneously twice daily. Two large, randomised studies showed that patients receiving danaparoid for 7 to 8 days following surgery developed significantly lower rates of DVT than patients receiving warfarin (patients with hip fracture 7 vs 21%; those with total hip replacement 14.6 vs 26.9%). Similarly, in a double-blind study in patients undergoing surgery for hip fracture, danaparoid was significantly more effective at reducing the incidence of DVT than aspirin (100mg twice daily) after treatment for 14 days following surgery (27.8 vs 44.3%). Randomised comparisons with dextran 70 and with heparin-dihydroergotamine (DHE) also suggest that danaparoid provides effective prophylaxis of DVT. The incidence of DVT in patients receiving danaparoid was significantly lower than in those receiving dextran 70 (10 vs 31%) or heparin-DHE(17 vs 33%). Finally, in a comparison of danaparoid with enoxaparin (40 mg/day subcutaneously) and dalteparin (5000 U/day subcutaneously) in patients undergoing surgery for hip fracture, there was no significant difference in the incidence of DVT between treatment groups (5.7 vs 15.4 vs 8.8%, respectively). Danaparoid has also been compared with UFH for the prophylaxis of DVT in 490 patients undergoing surgery for suspected gastrointestinal malignancy or lung cancer. There was no statistically significant difference in the frequency of positive leg scan results between treatment groups (danaparoid 7.9 vs UFH 11.2%). In two double-blind studies in patients with ischaemic stroke, no significant difference was observed between danaparoid (1250U once daily) and UFH (5000 U/day subcutaneously twice daily) in reducing the incidence of DVT (14.6 vs 19.8%) with treatment for a minimum of 9 days. However, in a separate study, danaparoid (750U twice daily) was significantly more effective than UFH (5000 U/day subcutaneously twice daily) in reducing the occurrence of DVT (9 vs 31%) when treatment was continued for 14 days. In a placebo-controlled, double-blind study, danaparoid (750U twice daily) significantly reduced the incidence of DVT compared with placebo (4 vs 28%). The ‘Trial of ORG 10172 (danaparoid) in Acute Stroke Treatment’ (TOAST) was a multicentre, placebo-controlled study in 1275 patients with acute or progressing ischaemic stroke to assess the effect of danaparoid on neurological outcomes. There was no significant difference in the frequency of favourable outcome (assessed using the Glasgow Outcome Scale and Barthel Index) at 7 days or at 3 months. There was also no significant difference between treatment groups in the frequency of very favourable outcome at 3 months; however, after 7 days’ treatment, significantly more patients receiving danaparoid reported very favourable outcomes compared with those receiving placebo. The incidence of DVT during the 3-month follow-up was significantly lower in patients who received danaparoid than in patients who received placebo. An assessor blind study has compared the efficacy of danaparoid with that of UFH for the treatment of venous thromboembolism in 188 patients. The frequency of recurrence or extension of DVT was significantly lower in patients receiving danaparoid 2000U subcutaneously twice daily (13%) than in those receiving UFH (28%) or in those receiving danaparoid 1250U subcutaneously twice daily (28%) when assessed after 5 to 8 days. Similar results were found 2 months after the initiation of study treatment. Treatment of Disseminated Intravascular Coagulation The use of danaparoid (1250U twice daily) in the treatment of disseminated intravascular coagulation (DIC) was examined in 85 patients in a randomised double-blind, double-dummy comparison with UFH (continuous intravenous infusion of 7 to 10 U/kg/h). There was no significant difference in the rate of change of the underlying condition between treatment groups after 5 days of treatment. Ten patients receiving danaparoid (23.3%) and 12 patients receiving UFH (28.6%) were considered to have an easing or recovery of their underlying condition. Similar numbers of patients in each group showed no change in (55.8 and 47.6%) or aggravation of (20.9 and 23.8%) the severity of their underlying condition. There was also no difference between treatment groups in DIC scores during the study. The only comparative study with danaparoid in the treatment of DIC has reported that 61.9% of patients receiving danaparoid experienced either disappearance or reduction of symptoms of DIC whereas 62% of patients receiving UFH showed either no change or aggravation of their symptoms. Heparin-Induced Thrombocytopenia A noncomparative study has reported that from a total of 667 patients who were receiving danaparoid for antithrombotic medication with associated HIT, 67 developed serious adverse events (including new or extension of thrombosis, skin rash, bleeding, and persistent of recurrent platelet count). Indirect comparison of danaparoid and lepirudin suggests that significantly fewer patients receiving danaparoid developed a major bleeding event than patients receiving lepirudin (2.5 vs 10.4%). Finally, in a prospective nonblind comparative study, one patient receiving danaparoid and three receiving dextran 70 died of HIT-associated thrombosis. Deep Vein Thrombosis In 9 studies which evaluated the efficacy and tolerability of danaparoid in the prophylaxis of DVT following surgery, the incidence of haemorrhagic complications did not differ significantly between danaparoid and the comparator agent. Most studies showed no significant difference between danaparoid and the comparator agent regarding blood loss and transfusion requirements during surgery; however, one study reported that significantly fewer patients receiving danaparoid required a postoperative blood transfusion compared with those receiving dextran 70 and, in a second study, more patients receiving danaparoid required intraoperative blood transfusion compared to those receiving heparin-DHE. Blood loss and mortality were generally similar between treatment groups. In the TOAST study, major bleeding events were significantly more frequent in patients receiving danaparoid during prophylaxis (7 days), within 10 days of starting therapy and throughout the 3-month period of observation than in those receiving placebo (p < 0.05 in all cases). In addition, serious brain bleeding during the initial 10 days of therapy, and minor bleeding during treatment and during the initial 10 days of therapy were also observed significantly more frequently in patients receiving danaparoid than in those receiving placebo (p < 0.05 in each case). Five patients with ischaemic strokes from three studies developed major bleeding complications; three of these patients were receiving danaparoid, one was receiving UFH, and one placebo. One case of a fatal haemorrhagic transformation associated with danaparoid treatment was reported. In patients receiving danaparoid for treatment of DVT, major bleeding occurred in two patients receiving UFH and two receiving danaparoid. Disseminated Intravascular Coagulation Data from the only comparative study with danaparoid in the treatment of DIC suggests that there are no significant tolerability differences between danaparoid and UFH. Three patients receiving UFH and no patients receiving danaparoid experienced bleeding-related adverse events. Throughout Western Europe danaparoid is approved for the treatment of HIT. For continued anticoagulation in patients with HIT, danaparoid should be administered intravenously as abolus of 2500U (1250U if bodyweight is 90kg) followed by a continuous intravenous infusion of 400 U/h for 2 hours, 300 U/h for the next 2 hours, then a maintenance infusion of 200 U/h for 5 days. In the US, danaparoid has received regulatory approval for the prophylaxis of postoperative DVT in patients undergoing elective hip replacement. In Europe, it has received regulatory approval for the prophylaxis of DVT in patients undergoing general or orthopaedic surgery. For DVT prophylaxis, danaparoid should be administered by subcutaneous injection at a dose of 750U twice daily beginning 1 to 4 hours before surgery and then not sooner than 2 hours after surgery. Treatment duration should be 7 to 10 days, and up to 14 days where necessary. In Japan, danaparoid has received regulatory approval for use in the treatment of DIC. The recommended normal adult dosage is 1250U twice daily via intravenous administration. Patients with moderately or severely impaired kidney or liver function, or impaired haemostasis should exercise caution when taking danaparoid, as delayed excretion may lead to haemorrhage. Dosage should be reduced or intervals between dosages increased if serum creatinine levels are ≥2 g/L. In patients with severe renal damage, consideration should be given to suspending treatment. Breast-feeding mothers should only be given danaparoid if clearly required, and the tolerability of danaparoid in infants and paediatric patients has not been confirmed. Finally, danaparoid is contraindicated in patients with haemorrhage (or at risk of haemorrhage), requiring haemodialysis, with severe liver damage, with hypersensitivity to danaparoid, with HIT who display cross-reactivity between danaparoid and HIT antibodies, with diabetic retinopathy and in those who have recently undergone brain, spinal or eye surgery.